WO2008037226A2 - Method of preparation of a soluble formulation of water-insoluble pentacyclic and tetracyclic terpenoids, a soluble formulation of a pentacyclic or tetracyclic terpenoid and a pharmaceutical composition containing this soluble formulation - Google Patents

Method of preparation of a soluble formulation of water-insoluble pentacyclic and tetracyclic terpenoids, a soluble formulation of a pentacyclic or tetracyclic terpenoid and a pharmaceutical composition containing this soluble formulation Download PDF

Info

Publication number
WO2008037226A2
WO2008037226A2 PCT/CZ2007/000088 CZ2007000088W WO2008037226A2 WO 2008037226 A2 WO2008037226 A2 WO 2008037226A2 CZ 2007000088 W CZ2007000088 W CZ 2007000088W WO 2008037226 A2 WO2008037226 A2 WO 2008037226A2
Authority
WO
WIPO (PCT)
Prior art keywords
group
terpenoid
substituents
general formula
bound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CZ2007/000088
Other languages
French (fr)
Other versions
WO2008037226A3 (en
Inventor
Jan Sarek
Marian Hajduch
Michal Svoboda
Katerina Novakova
Pavla Spacilova
Tomas Kubelka
David Biedermann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Matematicko-Fyzikalni Fakulta University Karlovy V Praze
I Q A AS
Palacky University Olomouc
Original Assignee
Matematicko-Fyzikalni Fakulta University Karlovy V Praze
I Q A AS
Palacky University Olomouc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Matematicko-Fyzikalni Fakulta University Karlovy V Praze, I Q A AS, Palacky University Olomouc filed Critical Matematicko-Fyzikalni Fakulta University Karlovy V Praze
Priority to CA2666437A priority Critical patent/CA2666437C/en
Priority to EP07801129.3A priority patent/EP2068882B1/en
Priority to US12/443,304 priority patent/US8653056B2/en
Priority to JP2009529508A priority patent/JP2010504921A/en
Publication of WO2008037226A2 publication Critical patent/WO2008037226A2/en
Publication of WO2008037226A3 publication Critical patent/WO2008037226A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0036—Nitrogen-containing hetero ring
    • C07J71/0042—Nitrogen only
    • C07J71/0047—Nitrogen only at position 2(3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids

Definitions

  • the invention relates to a method of preparation of a soluble formulation of water- insoluble pentacyclic and tetracyclic terpenoids, a soluble formulation of a pentacyclic or tetracyclic terpenoid and a pharmaceutical composition containing this soluble for- mulation.
  • Pentacyclic and tetracyclic terpenoids represent a group of natural substances - iso- prenoids, showing a large range of biological activities (Dzubak, P.; Hajduch, M.; Vy- dra, D.; Hustova, A.; Kvasnica, M.; Biedermann, D.; Markova, L.; Urban, M.; Sarek, J. Nat. Prod. Rep. 2006, 23, 394-411), thanks to which they are getting into the focus of the pharmaceutical industry.
  • neither modified nor semisynthetic derivatives of these natural substances possess optimum pharmacological properties.
  • the solvents commonly used in the chemical practice, such as chloroform, acetone, ethyl acetate etc., cannot be used for dissolving for pharmaceutical purposes, for the reason of their incompatibility with living organisms.
  • the triterpenoids reach the solubility between 10 and 50 mg/ml (WO 92/09553).
  • the inclusion compounds can be isolated from their solutions as solid substances in the form of powder by means of lyophilization.
  • native triterpenoid carboxylic acids having a free carboxylic functional group can be dissolved in water-based media, but not their functional derivatives or terpenoids that do not have carboxylic functional group.
  • the biologically active free triterpenoid acids having many disadvantageous pharmacological properties, e.g.
  • the carboxylic acid derivatives are even less compatible with water-based vehicles than the free acids.
  • Object of the invention is a method of preparation of a soluble formulation of water- insoluble pentacyclic and tetracyclic terpenoids, wherein the water-insoluble terpenoid having a free carboxylic, hydroxy or amino functional group is derivatized on this functional group with a substituent selected from the group comprising a) substituents of general formula X a bound to the hydroxy group of the terpenoid, wherein X a is -OC-R-COOH, wherein R is linear or branched C 1 to C 8 alkylene, linear or branched C 3 to C 8 oxaalkylene, linear or branched C 1 to C 8 alkenylene, C 6 cycloalkylene, C 6 cycloalkenylene, C 6 arylene unsubstituted or substituted with halogen, hydroxyl or amino group:
  • X a is -OC-R-COOH, wherein R is linear or branched Ci to C 8 alkylene, linear or branched C 3 to C 8 oxaalkylene, linear or branched C 1 to C 8 al- kenylene, C 6 cycloalkylene, C 6 cycloalkenylene, C 6 arylene unsubstituted or substituted with halogen, hydroxyl or amino group:
  • X b is -(CHa) n N + R 3 Y ' , wherein n is 2-8, R is linear or branched Ci to C 8 alkyl, optionally substituted with -OH, -NH 2 or halogen, and Y " is anion selected from the group comprising halogenide, sulphate, hydrogensulphate and triflate:
  • X c bound to the car- boxy group of the terpenoid, wherein X c je ⁇ (CH 2 ) n R + Y ⁇ , wherein n is 2-8, R + is protonated nitrogen-containing heterocycle containing 1-2 nitrogen atoms and 4-9 carbon atoms and containing at least one aromatic cycle and Y " is anion selected from the group comprising halogenide, sulphate, hydrogensulphate and triflate:
  • glycosylic substituents X e bound by ⁇ or ⁇ glycosidic bond to the carboxy group of the terpenoid wherein X e is selected from the group comprising glu- cosyl, galactosyl, arabinosyl, rhamnosyl, lactosyl, cellobiosyl, maltosyl and the 2-deoxyanalogues thereof:
  • glycosylic substituents X e bound by ⁇ or ⁇ glycosidic bound to the hydroxy group of the terpenoid wherein X e is selected from the group comprising glu- cosyl, galactosyl, arabinosyl, rhamnosyl, lactosyl, cellobiosyl, maltosyl and the 2-deoxyanalogues thereof: terpenoid moiety
  • the prepared derivative is dissolved in a solution containing water, a cyclodextrin and optionally pharmaceutically acceptable auxiliary substances, forming an inclusion derivative with the cyclodextrin.
  • the substituents of general formula X a are selected from the group comprising succinate, glutarate, 3 ',3 '-dimethylglutarate, 3',3'- dimethylsuccinate, tetrahydrophthalate, diglycolate or phthalate.
  • the substituents of general formula X e are selected from the group comprising glucosyl, galactosyl, lactosyl and the 2- deoxyanalogues thereof.
  • the cyclodextrin is selected from the group comprising native or substituted ⁇ -cyclodextrins and ⁇ -cyclodextrins.
  • Biocompatible organic solvents e.g. ethanol or propylene glycol
  • compounds fa- cilitating the formation of inclusion complexes such as e.g. alkali carbonates or hydrogen carbonates can be the auxiliary substances.
  • Object of the invention is further a soluble formulation of a pentacyclic or tetracyclic triterpenoid, containing an inclusion complex of the pentacyclic or tetracyclic terpe- noid having its carboxy, hydroxy or amino group derivatized with a substituent selected from the group comprising: a) substituents of general formula X a bound to the hydroxy group of the terpenoid, wherein X a is -OC-R-COOH, wherein R is linear or branched C 1 to C 8 alkylene, linear or branched C 3 to C 8 oxaalkylene, linear or branched Ci to C 8 alkenylene, C 6 cycloalkylene, C 6 cycloalkenylene, C 6 arylene unsubstituted or substituted with halogen, hydroxyl or amino group; b) substituents of general formula X a bound to the amino group of the terpenoid, wherein X a
  • 2-deoxyanalogues thereof g) glycosylic substituents X e bound by ⁇ or ⁇ glycosidic bound to the hydroxy group of the terpenoid, wherein X e is selected from the group comprising glu- cosyl, galactosyl, arabinosyl, rhamnosyl, lactosyl, cellobiosyl, maltosyl and the 2-deoxyanalogues thereof, with a cyclodextrin, and optionally water and pharmaceutically acceptable auxiliary substances.
  • the substituents of general formula X a are selected from the group comprising succinate, glutarate, 3 ',3 '-dimethylsuccinate, 3',3'-dimethylgrutarate, tetrahydrophthalate, diglycolate or phthalate.
  • the substituents of general formula X e are selected from the group comprising glucosyl, galactosyl, lactosyl and the 2- deoxyanalogues thereof.
  • the cyclodextrin is selected from the group comprising native or substituted ⁇ -cyclodextrins and ⁇ -cyclodextrins.
  • Biocompatible organic solvents e.g. ethanol or propylene glycol
  • compounds facilitating the formation of inclusion complexes such as e.g. alkali carbonates or hydrogen carbonates can be the auxiliary substances.
  • Object of the invention is further a pharmaceutical composition containing the soluble formulation according to the present invention and a pharmaceutically acceptable solvent.
  • the pharmaceutically acceptable solvent is water.
  • Fig. 1 represents the pharmacokinetic profile of the hemisuccinate 2b, administered in the form of aqueous solution of the inclusion complex with 2-hydroxypropyl- ⁇ - cyclodextrin at the oral administration to mice.
  • Fig. 2 represents the pharmacokinetic profile of the aldehyde 3, administered in the form of aqueous solution of the inclusion complex with 2-hydroxypropyl- ⁇ - cyclodextrin at the oral administration to mice.
  • Fig. 3 represents the pharmacokinetic profile of the hemisuccinate 3b, administered in the form of aqueous solution of the inclusion complex with 2-hydroxypropyl- ⁇ - cyclodextrin at the oral administration to mice.
  • Fig. 4 represents the pharmacokinetic profile of the hemisuccinate 5a, administered in the form of aqueous solution of the inclusion complex with 2-hydroxypropyl- ⁇ - cyclodextrin at the oral administration to mice.
  • Fig. 5 represents the pharmacokinetic profile of the diketone-dihemisuccinate 5e, ad- ministered in the form of aqueous solution of the inclusion complex with 2- hydroxypropyl- ⁇ -cyclodextrin at the oral administration to mice.
  • Fig. 6 represents the pharmacokinetic profile of the pyrazine 6a, administered in the form of aqueous solution of the inclusion complex with 2-hydroxypropyl- ⁇ - cyclodextrin at the oral administration to mice.
  • Fig. 7 represents the pharmacokinetic profile of the hemisuccinate 8a, administered in the form of aqueous solution of the inclusion complex with 2-hydroxypropyl- ⁇ - cyclodextrin at the oral administration to mice.
  • Fig. 8 represents the pharmacokinetic profiles of the compounds 5 c, 5d, 6, 7, 8 administered in the form of suspension with carboxymethyl cellulose (CMC) orally to mice.
  • Fig. 9 represents the pharmacokinetic profile of the 2-deoxygalactoside 4v at oral administration to mice.
  • Fig. 10 represents the pharmacokinetic profile of the glucoside 4i at oral administration to mice.
  • Fig. 11 represents the pharmacokinetic profile of the hemiglutarate 2i at oral adminis- tration to mice.
  • Fig. 12 represents the pharmacokinetic profile of the 3 ' ⁇ '-dimethylhemisuccinate 4t at oral administration to mice.
  • the method of preparation of the soluble formulations of water-insoluble pentacyclic and tetracyclic terpenoids consists of two steps: a) derivatization of the insoluble starting compound, b) preparation of the aqueous solution of the inclusion complex of the derivative and cyclodextrine. All compounds described in the examples and their evaluated properties are summarized in Table 1 and represented in formulas 1 to 8.
  • the general methods of derivatization of the insoluble pentacyclic and tetracyclic triterpenoids are designated H-I, H-I*, H-2, H-3, H-4, H-5, H-6, H-6*, H-7, H-7*, H- 8, H-9, K-I, K-2, K-3 and are herein below demonstrated in specific examples.
  • Method designations without asterisk stand for direct derivatization methods, whereas method designations with asterisk stand for derivatization methods going via benzyl- ester of triterpenic acid and leading to derivatives with two free carboxylic groups - one formed by the derivatization and the other being skeletal carboxylic group.
  • the general methods of the preparation of the inclusion complex, comprising the dissolution of the substance are designated A and B.
  • the chromatographically uniform hemisuccinate 5a was crystallized from the mixture acetonitrile/water.
  • 13 C NMR spectrum 16.1, 16.5, 16.7, 16.8, 18.0, 19.7, 19.8, 21.0, 23.5, 25.9, 27.4, 27.8, 27.9, 28.4, 28.9, 29.2, 34.5, 37.1, 37.8, 38.5, 41.5, 45.5, 46.1, 50.8, 50.8, 53.4, 55.4, 81.2, 150.6, 168.1, 171.0, 171.9, 177.6, 189.2, 194.3.
  • the evaporate was purified by column chromatography on silica gel by gradient elution from 10% ethyl acetate in hexane to 50% ethylacetate.
  • the chromatographically uniform benzyl betulinate hemisuccinate was used in the next step without purification.
  • the reaction mixture was then acidified with acetic acid to reach pH 6 and evaporated on a rotary vacuum evaporator. To the evaporate, water was added and the resulting suspension was filtered and washed with water. The precipitate was dried in exsiccator over phosphorus(V) oxide.
  • Example 9 Preparation of 2-deoxygalactoside 4k (method H-4) i) Into a solution of the triterpenic hydroxyderivative 4g (500 mg; 1.0 mmol) in dry acetonitrile (30 ml), tri-Oacetylgalactal (1.2 mmol), molecular sieve 4A (500 mg), lithium bromide (730 mg) and dried cation exchange resin in H + cycle (900 mg) were added. The reaction mixture was stirred at room temperature for 12 hours. The course of the reaction was monitored by thin-layer chromatography, the mobile phase being hexane: ethyl acetate 2:1.
  • reaction mixture was then filtered through a diatoma- ceous earth layer and the column was then washed with ethyl acetate.
  • the reaction mixture was diluted with water (50 ml), extracted with ethyl acetate (2x 20 ml) and the organic phase was evaporated on a rotary vacuum evaporator.
  • the evaporate was dis- solved in chloroform (5 ml) and the solution was poured over a short column of silica gel (elution with ethyl acetate).
  • the eluate was evaporated on a rotary vacuum evaporator.
  • the crude product was then separated by column chromatography on silica gel, elution with toluene.
  • the reaction mixture was then filtered through a diatoma- ceous earth layer, and the column was washed with ethyl acetate.
  • the reaction mixture was diluted with water (50 ml), extracted with ethyl acetate (2x 20 ml) and the organic phase was evaporated on a rotary vacuum evaporator. The evaporate was dissolved in chloroform (5 ml) and the solution was poured over a short column of silica gel (elution with ethyl acetate). The eluate was evaporated on a rotary vacuum evapo- rator. The crude product was then separated by column chromatography on silica gel, eluted with toluene.
  • the obtained crude 21-oxoacid benzyl glycolate (509 mg; 79 %) was used in the next step.
  • ii) Into a solution of 21-oxoacid benzyl glycolate (350 mg; 0.5 mmol) in the mixture of tetrahydrofurane (20 ml) and methanol (10 ml), palladium on carbon (75 mg; 10%) and 1,4-cyclohexadiene (473 ⁇ l; 5 mmol) were added and the reaction mixture was stirred at room temperature for 20 h. The course of the reaction was monitored using TLC (toluene/diethyl ether 4:1).
  • Example 15 Preparation of quarternary ammonium salt 4o (method K-2) i) Into a suspension of acid 4 (5.O g; 10 mmol) in the mixture of dichloro- methane (150 ml) and acetonitrile (5 ml), potassium carbonate (2 g; 14.2 mmol) and 1,2-dibromoethane (1.65 ml; 13.5 mmol) were added and the reaction mixture was stirred at room temperature. The course of the reaction was monitored by TLC (tolu- ene/ether 6:1). After all the reactant was consumed, the base was removed by filtration, the mixture was diluted with ten-fold excess of water and extracted into ethyl acetate.
  • TLC tolu- ene/ether 6:1
  • the reaction mixture was then cooled down, diluted with ten-fold excess of water and extracted into ethyl acetate. Combined organic phases were shaken three times with 5% HCl, three times with water, dried with magnesium sulphate and the solvents were evaporated on a rotary vacuum evaporator. The evaporate was purified by column chromatography on silica gel by gradient elution from 8% ethyl acetate in hexane to 25% ethyl acetate in hexane.
  • Method A In a mixture of water (26.0 ml), sodium hydrogencarbonate solution (5.0 ml; saturated solution) and ethanol (7.0 ml; 99%), 2-hydroxypropyl- ⁇ - cyklodextrin (10.0 g) is dissolved at the temperature of 50 0 C under vigorous stirring. Into the resulting colourless, viscous solution, soluble triterpene derivative (1.50 g) is added at once and the mixture is again vigorously stirred at the temperature of 50 °C. 20 to 40 min of stirring is usually necessary for a complete dissolution.
  • the resulting clear solution is cooled to room temperature, filtered with a syringe filter (hydrophilic, pore size 0.22 ⁇ m) in order to be sterile and is placed in a refrigerator.
  • the obtained solution can be stored in a freezer at - 20 °C until further use without any perceptible decomposition.
  • Method B In a mixture of water (14.0 ml) and propylene glycol (6.0 ml), 2- hydroxypropyl- ⁇ -cyklodextrin (7.00 g) is dissolved at the temperature of 50 °C under vigorous stirring. Into the resulting colourless, viscous solution, soluble triterpene derivate (1.00 g) is added at once and is again vigorously stirred at the temperature of
  • the resulting clear solution is cooled to room temperature, filtered with a syringe filter (hydrophilic, pore size 0.22 ⁇ m) in order to be sterile and is placed in a refrigerator.
  • the obtained solution can be stored in a freezer at - 20 °C until further use without any perceptible decomposition.
  • HPLC-ESI MS technique was used or the determination of the concentration of dissolved triterpenoids.
  • the samples were measured in one analytical batch with calibration solutions and blind control.
  • the sample for the measurement was prepared from 50 ⁇ l of aqueous solution containing the inclusion compound by dilution with metha- nol to the volume of 10 ml. Subsequently, 10 ⁇ l of the sample solution after the first dilution is further diluted to 1 ml by the mobile phase.
  • the blind control was obtained from 50 ⁇ l of pre-prepared aqueous solution of 2-hydroxypropyl- ⁇ -cyklodextrin by dilution with methanol to 10 ml. Subsequently, 10 ⁇ l of the blind control solution after the first dilution is further diluted to 1 ml by methanol.
  • mice The pharmacokinetic profiles of selected derivatives at oral administration to mice (compounds 2b, 3, 3b, 5a, 5f, 6a, 8a, 4v, 4i, 2i, 4t were administered as cyclodex- trin formulations, compounds 5c, 5d, 6, 7, 8 as carboxymethyl cellulose suspensions) are shown in Fig. 1 to 12.
  • the results prove oral availability of the soluble cyclodex- trin terpenoid formulations, but not of the insoluble suspensions.
  • R 2 CH 2 C 6 H 5 CH 2 C 6 H 5
  • R 1 CO(CH 2 ) 2 CO 2 H
  • R 2 H

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nanotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention relates to a method of preparation of a soluble formulation of water-insoluble pentacyclic and tetracyclic terpenoids, wherein the water-insoluble terpenoid having a free carboxylic, hydroxy or amino functional group is derivatized on this functional group with a substituent selected from the group comprising substituents of general formula Xa bound to the hydroxy group of the terpenoid, wherein Xa is -OC-R-COOH, substituents of general formula Xa bound to the amino group of the terpenoid, wherein Xa is -OC-R-COOH, quarternary ammonium substituents of general formula Xb bound to the carboxy group of the terpenoid, wherein Xb is -(CH2)nN+R3Y-, quarternary ammonium substituents of general formula Xc bound to the carboxy group of the terpenoid, wherein Xc je -(CH2)nR+Y-, substituents of general formula Xd bound to the carboxy group of the terpenoid, wherein Xd represents -R-COOH, glycosylic substituents Xe bound by alpha or beta glycosidic bond to the hydroxy group or to the carboxy group of the terpenoid, wherein Xe is selected from the group comprising glucosyl, galactosyl, arabinosyl, rhamnosyl, lactosyl, cellobiosyl, maltosyl and the 2-deoxyanalogues thereof, and subsequently, the prepared derivative is dissolved in the solution containing water, a cyclodextrin and optionally pharmaceutically acceptable auxiliary substances, forming an inclusion derivative with the cyclodextrin. Object of the invention is further a soluble formulation of a pentacyclic or tetracyclic triterpenoid, containing an inclusion complex of the derivatized pentacyclic or tetracyclic terpenoid with a cyclodextrin, and optionally water and pharmaceutically acceptable auxiliary substances and further a pharmaceutical composition containing the soluble formulation.

Description

Method of preparation of a soluble formulation of water-insoluble pentacvclic and tetracyclic terpenoids, a soluble formulation of a pentacyclic or tetracyclic terpenoid and a pharmaceutical composition containing this soluble formulation
Technical Field
The invention relates to a method of preparation of a soluble formulation of water- insoluble pentacyclic and tetracyclic terpenoids, a soluble formulation of a pentacyclic or tetracyclic terpenoid and a pharmaceutical composition containing this soluble for- mulation.
Background Art
Pentacyclic and tetracyclic terpenoids represent a group of natural substances - iso- prenoids, showing a large range of biological activities (Dzubak, P.; Hajduch, M.; Vy- dra, D.; Hustova, A.; Kvasnica, M.; Biedermann, D.; Markova, L.; Urban, M.; Sarek, J. Nat. Prod. Rep. 2006, 23, 394-411), thanks to which they are getting into the focus of the pharmaceutical industry. However, neither modified nor semisynthetic derivatives of these natural substances possess optimum pharmacological properties. Among their disadvantages belong namely low solubility in water-based media and further disadvantageous pharmacokinetic indicators such as low biological availability, short half-time of excretion and insufficient stability, which are unsuitable for carrying out in vivo tests in animals as well as for subsequent use in treatment of patients.
The pentacyclic and tetracyclic terpenoids are almost water-insoluble, since they have rigid lipophilic skeleton, composed of 25 - 30 carbon atoms, even if they bear polar functional groups such as -OH, -COOH, =O, -NH2 etc. The solvents commonly used in the chemical practice, such as chloroform, acetone, ethyl acetate etc., cannot be used for dissolving for pharmaceutical purposes, for the reason of their incompatibility with living organisms. In the art it is known that in the presence of alkali carbonates or hydrogencarbonates, pentacyclic triterpenoid acids form inclusion compounds with cyclodextrins, these inclusion compounds being soluble in water-based media with the addition of suitable additives (WO 92/09553). It is taught that the highest solubility of triterpenoid acids can be achieved with the use of higher cyclodextrins, namely β and γ, and lower alcohols (methanol) or glycols (propylene glycol, butandiol) are used as additives (Uekama K., Hirayama F., Me T.: Chem. Rev. 1998, 98, 2045-2076, Hedges A. R.: Chem. Rev. 1998, 98, 2035-2044). In the vehicles used, the triterpenoids reach the solubility between 10 and 50 mg/ml (WO 92/09553). The inclusion compounds can be isolated from their solutions as solid substances in the form of powder by means of lyophilization. However, only native triterpenoid carboxylic acids having a free carboxylic functional group can be dissolved in water-based media, but not their functional derivatives or terpenoids that do not have carboxylic functional group. Furthermore, in the pharmaceutical practice, the biologically active free triterpenoid acids, having many disadvantageous pharmacological properties, e.g. difficult purificability and instability, are often converted into derivatives bringing often a slower metaboli- zation (increase of the half-life), increase of stability or functioning as prodrug. One type of these derivatives are various biologically cleavable esters, such as e.g. mor- pholinoethyl esters, acetoxymethyl esters, heptyl esters etc. (Gewehr M., Kunz H.: Synthesis 1997, 1499; Urban M., Sarek J., Tislerova L5 Dzubak P., Hajduch M.: Bio- org. Med. Chem. 2005, 13, 5527)
In general, the carboxylic acid derivatives are even less compatible with water-based vehicles than the free acids. For the exploitation of the carboxylic acid derivatives in the pharmaceutical practice, it is necessary to find a formulation enabling their use with the water-based vehicles.
From the above given reasons it is clear that for further development, it is necessary to prepare the derivatives of the insoluble biologically active pentacyclic and tetracyclic terpenoids that are soluble in water-based media, are bioavailable (preferably orally available), have a suitable half-time of excretion and are stable, i.e. that have optimum pharmacokinetic parameters.
Disclosure of Invention
Object of the invention is a method of preparation of a soluble formulation of water- insoluble pentacyclic and tetracyclic terpenoids, wherein the water-insoluble terpenoid having a free carboxylic, hydroxy or amino functional group is derivatized on this functional group with a substituent selected from the group comprising a) substituents of general formula Xa bound to the hydroxy group of the terpenoid, wherein Xa is -OC-R-COOH, wherein R is linear or branched C1 to C8 alkylene, linear or branched C3 to C8 oxaalkylene, linear or branched C1 to C8 alkenylene, C6 cycloalkylene, C6 cycloalkenylene, C6 arylene unsubstituted or substituted with halogen, hydroxyl or amino group:
terpenoid / derivatization terpenoid / moiety A. *~ moiety ,<£.
/ ^OH / ^0Xa
b) substituents of general formula Xa bound to the amino group of the terpenoid, wherein Xa is -OC-R-COOH, wherein R is linear or branched Ci to C8 alkylene, linear or branched C3 to C8 oxaalkylene, linear or branched C1 to C8 al- kenylene, C6 cycloalkylene, C6 cycloalkenylene, C6 arylene unsubstituted or substituted with halogen, hydroxyl or amino group:
terpenoid moiety
Figure imgf000004_0001
c) quarternary ammonium substituents of general formula Xb bound to the car- boxy group of the terpenoid, wherein Xb is -(CHa)nN+R3Y', wherein n is 2-8, R is linear or branched Ci to C8 alkyl, optionally substituted with -OH, -NH2 or halogen, and Y" is anion selected from the group comprising halogenide, sulphate, hydrogensulphate and triflate:
terpenoid / derivatization terpenoid /
Figure imgf000004_0002
d) quarternary ammonium substituents of general formula Xc bound to the car- boxy group of the terpenoid, wherein Xc je ~(CH2)nR+Y~, wherein n is 2-8, R+ is protonated nitrogen-containing heterocycle containing 1-2 nitrogen atoms and 4-9 carbon atoms and containing at least one aromatic cycle and Y" is anion selected from the group comprising halogenide, sulphate, hydrogensulphate and triflate:
terpenoid / derivatization terpenoid / moiety /L *" moiety /
/ CO2H / XO2X0 e) substituents of general formula Xd bound to the carboxy group of the terpenoid, wherein Xd represents -R-COOH, wherein R is linear or branched Cj to C4 alkylene, linear or branched Ci to C4 alkenylene, C6 arylene unsubstituted or substituted with halogen, hydroxy or amino group: terpenoid moiety
Figure imgf000005_0001
f) glycosylic substituents Xe bound by α or β glycosidic bond to the carboxy group of the terpenoid, wherein Xe is selected from the group comprising glu- cosyl, galactosyl, arabinosyl, rhamnosyl, lactosyl, cellobiosyl, maltosyl and the 2-deoxyanalogues thereof:
terpenoid / derivatization terpenoid /
Figure imgf000005_0002
g) glycosylic substituents Xe bound by α or β glycosidic bound to the hydroxy group of the terpenoid, wherein Xe is selected from the group comprising glu- cosyl, galactosyl, arabinosyl, rhamnosyl, lactosyl, cellobiosyl, maltosyl and the 2-deoxyanalogues thereof: terpenoid moiety
Figure imgf000005_0003
and subsequently, the prepared derivative is dissolved in a solution containing water, a cyclodextrin and optionally pharmaceutically acceptable auxiliary substances, forming an inclusion derivative with the cyclodextrin.
In a preferred embodiment of the invention, the substituents of general formula Xa are selected from the group comprising succinate, glutarate, 3 ',3 '-dimethylglutarate, 3',3'- dimethylsuccinate, tetrahydrophthalate, diglycolate or phthalate.
In a preferred embodiment of the invention, the substituents of general formula Xb are choline esters, wherein n=2, R=CH3. In a preferred embodiment of the invention, the substituents of general formμla X° are pyridiniurn salts, wherein n=2, R+=PyH+, Y "=Br".
In a preferred embodiment of the invention, the substituents of general formula Xd are glycolates, wherein R=CH2.
In a preferred embodiment of the invention, the substituents of general formula Xe are selected from the group comprising glucosyl, galactosyl, lactosyl and the 2- deoxyanalogues thereof.
In a preferred embodiment of the invention, the cyclodextrin is selected from the group comprising native or substituted β-cyclodextrins and γ-cyclodextrins.
Biocompatible organic solvents, e.g. ethanol or propylene glycol, and compounds fa- cilitating the formation of inclusion complexes, such as e.g. alkali carbonates or hydrogen carbonates can be the auxiliary substances.
Object of the invention is further a soluble formulation of a pentacyclic or tetracyclic triterpenoid, containing an inclusion complex of the pentacyclic or tetracyclic terpe- noid having its carboxy, hydroxy or amino group derivatized with a substituent selected from the group comprising: a) substituents of general formula Xa bound to the hydroxy group of the terpenoid, wherein Xa is -OC-R-COOH, wherein R is linear or branched C1 to C8 alkylene, linear or branched C3 to C8 oxaalkylene, linear or branched Ci to C8 alkenylene, C6 cycloalkylene, C6 cycloalkenylene, C6 arylene unsubstituted or substituted with halogen, hydroxyl or amino group; b) substituents of general formula Xa bound to the amino group of the terpenoid, wherein Xa is -OC-R-COOH, wherein R is linear or branched Ci to Cs alkylene, linear or branched C3 to C8 oxaalkylene, linear or branched Ci to C8 al- kenylene, C6 cycloalkylene, C6 cycloalkenylene, C6 arylene unsubstituted or substituted with halogen, hydroxyl or amino group; c) quarternary ammonium substituents of general formula Xb bound to the car- boxy group of the terpenoid, wherein Xb is -(CH2)J1N+R3Y', wherein n is 2-8, R is linear or branched Cj to C8 alkyl, optionally substituted with -OH, -NH2 or halogen, and Y" is anion selected from the group comprising halogenide, sulphate, hydrogensulphate and triflate; d) quarternary ammonium substituents of general formula Xc bound to the car- boxy group of the terpenoid, wherein X0Je -(CH2)nR+Y", wherein n is 2-8, R+ is protonated nitrogen-containing heterocycle containing 1-2 nitrogen atoms and
4-9 carbon atoms and containing at least one aromatic cycle and Y" is anion selected from the group comprising halogenide, sulphate, hydrogensulphate and triflate; e) substituents of general formula Xd bound to the carboxy group of the terpe- noid, wherein Xd represents -R-COOH, wherein R is linear or branched Ci to
C4 alkylene, linear or branched C1 to C4 alkenylene, C6 arylene unsubstituted or substituted with halogen, hydroxy or amino group; f) glycosylic substituents Xe bound by α or β glycosidic bound to the carboxy group of the terpenoid, wherein Xe is selected from the group comprising glu- cosyl, galactosyl, arabinosyl, rhamnosyl, lactosyl, cellobiosyl, maltosyl and the
2-deoxyanalogues thereof; g) glycosylic substituents Xe bound by α or β glycosidic bound to the hydroxy group of the terpenoid, wherein Xe is selected from the group comprising glu- cosyl, galactosyl, arabinosyl, rhamnosyl, lactosyl, cellobiosyl, maltosyl and the 2-deoxyanalogues thereof, with a cyclodextrin, and optionally water and pharmaceutically acceptable auxiliary substances.
In a preferred embodiment of the invention, the substituents of general formula Xa are selected from the group comprising succinate, glutarate, 3 ',3 '-dimethylsuccinate, 3',3'-dimethylgrutarate, tetrahydrophthalate, diglycolate or phthalate.
In a preferred embodiment of the invention, the substituents of general formula Xb are choline esters, wherein n=2, R=CH3.
In a preferred embodiment of the invention, the substituents of general formula X° are pyridinium salts, wherein n=2, R+=PyH+, Y"=Br". In a preferred embodiment of the invention, the substituents of general formula Xd are glycolates, wherein R=CH2.
In a preferred embodiment of the invention, the substituents of general formula Xe are selected from the group comprising glucosyl, galactosyl, lactosyl and the 2- deoxyanalogues thereof.
In a preferred embodiment of the invention, the cyclodextrin is selected from the group comprising native or substituted β-cyclodextrins and γ-cyclodextrins.
Biocompatible organic solvents, e.g. ethanol or propylene glycol, and compounds facilitating the formation of inclusion complexes, such as e.g. alkali carbonates or hydrogen carbonates can be the auxiliary substances.
Object of the invention is further a pharmaceutical composition containing the soluble formulation according to the present invention and a pharmaceutically acceptable solvent.
In a preferred embodiment according to the invention, the pharmaceutically acceptable solvent is water. '
Figures
Fig. 1 represents the pharmacokinetic profile of the hemisuccinate 2b, administered in the form of aqueous solution of the inclusion complex with 2-hydroxypropyl-γ- cyclodextrin at the oral administration to mice.
Fig. 2 represents the pharmacokinetic profile of the aldehyde 3, administered in the form of aqueous solution of the inclusion complex with 2-hydroxypropyl-γ- cyclodextrin at the oral administration to mice.
Fig. 3 represents the pharmacokinetic profile of the hemisuccinate 3b, administered in the form of aqueous solution of the inclusion complex with 2-hydroxypropyl-γ- cyclodextrin at the oral administration to mice. Fig. 4 represents the pharmacokinetic profile of the hemisuccinate 5a, administered in the form of aqueous solution of the inclusion complex with 2-hydroxypropyl-γ- cyclodextrin at the oral administration to mice.
Fig. 5 represents the pharmacokinetic profile of the diketone-dihemisuccinate 5e, ad- ministered in the form of aqueous solution of the inclusion complex with 2- hydroxypropyl-γ-cyclodextrin at the oral administration to mice. Fig. 6 represents the pharmacokinetic profile of the pyrazine 6a, administered in the form of aqueous solution of the inclusion complex with 2-hydroxypropyl-γ- cyclodextrin at the oral administration to mice. Fig. 7 represents the pharmacokinetic profile of the hemisuccinate 8a, administered in the form of aqueous solution of the inclusion complex with 2-hydroxypropyl-γ- cyclodextrin at the oral administration to mice.
Fig. 8 represents the pharmacokinetic profiles of the compounds 5 c, 5d, 6, 7, 8 administered in the form of suspension with carboxymethyl cellulose (CMC) orally to mice. Fig. 9 represents the pharmacokinetic profile of the 2-deoxygalactoside 4v at oral administration to mice.
Fig. 10 represents the pharmacokinetic profile of the glucoside 4i at oral administration to mice. Fig. 11 represents the pharmacokinetic profile of the hemiglutarate 2i at oral adminis- tration to mice.
Fig. 12 represents the pharmacokinetic profile of the 3 '^'-dimethylhemisuccinate 4t at oral administration to mice.
Examples
The method of preparation of the soluble formulations of water-insoluble pentacyclic and tetracyclic terpenoids consists of two steps: a) derivatization of the insoluble starting compound, b) preparation of the aqueous solution of the inclusion complex of the derivative and cyclodextrine. All compounds described in the examples and their evaluated properties are summarized in Table 1 and represented in formulas 1 to 8.
The general methods of derivatization of the insoluble pentacyclic and tetracyclic triterpenoids are designated H-I, H-I*, H-2, H-3, H-4, H-5, H-6, H-6*, H-7, H-7*, H- 8, H-9, K-I, K-2, K-3 and are herein below demonstrated in specific examples. Method designations without asterisk stand for direct derivatization methods, whereas method designations with asterisk stand for derivatization methods going via benzyl- ester of triterpenic acid and leading to derivatives with two free carboxylic groups - one formed by the derivatization and the other being skeletal carboxylic group. The general methods of the preparation of the inclusion complex, comprising the dissolution of the substance, are designated A and B.
a) Derivatization of the insoluble substance Example 1
Preparation of betulin-dihemisuccinate (Ia) (method H-I)
Into a solution of betulin (1) (500 mg; 1.13 mmol) in pyridine (20 ml), succinic anhydride (1.2 g; 12.0 mmol) and N,iV-dimethylaminopyridine, hereinafter DMAP (1.2 g; 10.0 mmol), were added and the reaction mixture was refluxed under stirring for 12 h. The course of the reaction was monitored by thin-layer chromatography, hereinafter TLC (hexane/ethyl acetate 1:1). The reaction mixture was then cooled down, diluted with ten-fold excess of water and extracted into ethyl acetate. Combined organic phases were shaken three times with 5% HCl, three times with water, dried with magnesium sulphate and the solvents were vacuum-dried at a rotary vacuum evaporator. The evaporate was purified by column chromatography on silica gel by gradient elu- tion from 20% ethyl acetate in hexane to 100% ethyl acetate. The chromatographically uniform dihemisuccinate Ia was lyophilised from tert-butyl alcohol. The obtained hemisuccinate Ia (387 mg; 67 %) had the melting point 107 °C, [α]D = 10° (c = 0.44). 13C NMR spectrum: 14.8, 16.0, 16.1, 16.5, 18.1, 19.1, 20.8, 23.6, 25.2, 27.0, 27.9, 29.0, 29.0, 29.1, 29.3, 29.5, 29.6, 34.1, 34.4, 37.0, 37.6, 37.8, 38.4, 40.9, 42.7, 46.4, 47.7, 48.8, 50.3, 55.4, 63.2, 81.5, 109.9, 150.1, 171.8, 172.4, 177.8, 177.8.
Example 2
Preparation of hemisuccinate 5a (method H-I) Into a solution of hydroxy diketone 5 (500 mg; 1.0 mmol) in the mixture of pyridine (15 ml) and tetrahydrofurane, hereinafter THF (5 ml), succinic anhydride (900 mg; 9.0 mmol) and DMAP (982 mg; 8.0 mmol) were added and the reaction mixture was refluxed under stirring for 12 h. The course of the reaction was monitored by TLC (hexane/ethyl acetate 1:1). The reaction mixture was then cooled down and worked-up analogically as in the preparation of the compound Ia. The chromatographically uniform hemisuccinate 5a was crystallized from the mixture acetonitrile/water. The obtained hemisuccinate 5a (383 mg; 64 %) had the m.p. 154 - 157 °C, [α]D = -99° (c = 0.24). 13C NMR spectrum: 16.1, 16.5, 16.7, 16.8, 18.0, 19.7, 19.8, 21.0, 23.5, 25.9, 27.4, 27.8, 27.9, 28.4, 28.9, 29.2, 34.5, 37.1, 37.8, 38.5, 41.5, 45.5, 46.1, 50.8, 50.8, 53.4, 55.4, 81.2, 150.6, 168.1, 171.0, 171.9, 177.6, 189.2, 194.3.
Example 3
Preparation of hemisuccinate 8a (method H-I) Into a solution of amino alcohol 8 (500 mg; 1.1 mmol) in tetrahydrofurane (10 ml), succinic anhydride (900 mg; 9.0 mmol) was added and the reaction mixture was refluxed under stirring for 5 h. The course of the reaction was monitored by TLC (hexane/ethyl acetate 1:1). The reaction mixture was then cooled down and worked-up analogically as in the preparation of the compound Ia. The chromatographically uniform hemisuccinate 8a was crystallized from the mixture acetonitrile/water. The obtained hemisuccinate 8a (406 mg; 67 %) had m.p. 283 - 284 0C, [α]D = +65° (c = 0.34).
Example 4 Preparation of free acid hemisuccinate 2e (method H-I*)
To a mixture of betulinic acid (2) (500 mg; 1.1 mmol) and potassium carbonate (276 mg; 2.0 mmol) in N, N-dimethylformamide, hereinafter DMF (20 ml), benzylbromide (178 μl; 1,5 mmol) was added and the reaction mixture was stirred at room temperature for 24 h. The course of the reaction was monitored by TLC (tolu- ene/diethyl ether 10:1). The reaction mixture was then diluted with ten-fold excess of water and extracted into ethyl acetate. Combined organic phases were shaken three times with 5% HCl, three times with water, dried with magnesium sulphate and the solvents were evaporated at a rotary vacuum evaporator. The evaporate was purified by column chromatography on silica gel, toluene being the mobile phase. The obtained crude benzyl betulinate (517 mg; 86 %) was used without purification in the next step.
To a solution of benzyl betulinate (500 mg; 0.9 mmol) in pyridine (20 ml), succinic anhydride (900 mg; 9.0 mmol) and DMAP (982 mg; 8.0 mmol) were added and the reaction mixture was refluxed under stirring for 15 h. The course of the reaction was monitored by TLC (hexahe/ethyl acetate 1:1). The reaction mixture was then cooled down, diluted with ten-fold excess of water and extracted into ethyl acetate. Combined organic extracts were shaken three times with 5% HCl, three times with water, dried with magnesium sulphate and the solvents were evaporated at a rotary vacuum evaporator. The evaporate was purified by column chromatography on silica gel by gradient elution from 10% ethyl acetate in hexane to 50% ethylacetate. The chromatographically uniform benzyl betulinate hemisuccinate was used in the next step without purification.
To a solution of benzyl betulinate hemisuccinate (389 mg; 0,6 mmol) in the mixture of tetrahydrofurane (10 ml) and methanol (5 ml) palladium on carbon (50 mg; 10%) and 1,4-cyklohexadiene (568 μl; 6 mmol) were added and the reaction mixture was stirred at room temperature for 22 h. The course of the reaction was monitored by TLC (hexane/ethyl acetate 1:1). The reaction mixture was then filtered through diato- maceous earth and the eluate was evaporated at a rotary vacuum evaporator. By the crystallization of the evaporate from benzene, hemisuccinate 2e (366 mg; 91 %) having m.p. 265 0C, [α]D = 15° (c = 0.37) was obtained. 13C NMR spectrum: 14.6, 16.2, 16.2, 16.6, 18.2, 19.3, 20.9, 23.6, 25.4, 28.0, 29.2, 29.4, 29.7, 30.5, 32.1, 34.1, 37.1, 37.1, 37.9, 38.2, 38.4, 40.7, 42.4, 46.9, 49.2, 50.2, 55.3, 56.5, 81.5, 109.7, 150.3, 171.7, 178.3, 182.7.
Example 5
Preparation of hemiphthalate 2c (method H-2)
To a solution of ethyl betulinate (2a) (500 mg; 1.0 mmol) in pyridine (20 ml) phthalic anhydride (1.48 g; 10.0 mmol) and DMAP (366 mg; 3.0 mmol) were added and the reaction mixture was refluxed under stirring for 28 h. The course of the reaction was monitored by TLC (hexane/ethyl acetate 1:1). The reaction mixture was then cooled down and worked up and the product was purified analogically as in the preparation of the compound Ia. The chromatographically uniform hemiphthalate 2c was lyophilized from tert-butyl alcohol. The obtained hemiphthalate 2c (335 mg; 53 %) had m.p. 131 0C, [α]D = 26° (c = 0.45).
Example 6
Preparation of betuline dihemiphthalate (Ib) (method H-2)
To a solution of betuline (1) (500 mg; 1.13 mmol) in pyridine (20 ml), phthalic anhydride (1.33 g; 9.0 mmol) and DMAP (366 mg; 3.0 mmol) were added and the reaction mixture was refluxed under stirring for 37 h. The course of the reaction was monitored by TLC (hexane/ethyl acetate 1:1). The reaction mixture was then cooled down and worked up and the product was purified analogically as in the preparation of the compound Ia. The chromatographically uniform dihemiphthalate Ib was lyophilized from tert-butyl alcohol. The obtained dihemiphthalate Ib (633 mg; 76 %) had m.p. 178 - 180 0C5 [α]D = 28° (c = 0.55).
Example 7
Preparation of glucoside 4i (method H-3) i) To a solution of ethylester 4g (1.00 g; 2.07 rnrnol) in dry acetonitrile (25 ml)
2,3,4,6-tetraacetyl-α-D-glucopyranosyl bromide (1.7 g; 4.1 mmol) and mercury cyanide (782 mg; 3.1 mmol) and the mixture was then refluxed under reflux condenser with the exclusion of air moisture. The course of the reaction was monitored by TLC (toluene/ether 6:1). The cooled-down reaction mixture was then bubbled through with moist hydrogensulphide, filtered through diatomaceous earth, the filtrate was diluted with ten-fold excess of water and extracted into ethyl acetate. Combined organic extracts were shaken three times with water, dried with magnesium sulphate and the solvents were evaporated at a rotary vacuum evaporator. The evaporate was purified by column chromatography on silica gel, toluene with diethyl ether gradient being the mobile phase. The obtained acetylated glucoside 4h (550 mg; 33 %) had m.ρ. 110 0C, [α]D = -33° (c = 0.32). IR spectrum: 1246 (C-O); 1609 (C=C); 1697, 1754 (C=O). 1H NMR spectrum: 0.73 s, 3H; 0.87 s, 3H; 0.90 s, 3H; 0.92 s, 3H; 1.02 s, 3H; 1.20 s, 3H; 1.22 s, 3H; (7xCH3); 1.26 t, 3H (J= 7.4; -CH2-CH3); 2.01 s, 3H; 2.03 s, 3H; 2.04 s, 3H; 2.09 s, 3H (4xCH3COO); 2.46 d, IH (J=I 8.6; H-22b); 2.46 m, IH (ΣJ=12.0; H- 16β); 2.68 dd, IH (J1=IZ?. J2=3.2; H-13β); 3.08 m, IH, (ΣJ=16.4; H-3α); 3.20 septet, IH (J=7.1; H-20); 3.69 m, IH (J-20.0; H-5'); 4.10-4.28 m, 4H (O-CH2, H-6'a5b); 4.54 d, IH (J=8.1; H-I '); 5.01-5.09 m, 2H (H-4\ H-2'); 5.18-5.24 m, IH (ΣJ=24; H-3'). MS ESI m/z (%): [For C46H64O13, M+ 828], 829 ([M-f-H] +, 10); (851 ([M+Na]+, 40). Elemental analysis for C46H64O13: calculated C 66.64 %, H 8.27 %; found C 61.97 %, H 8.12 %. ii) The obtained acetylated glucoside 4h (330 mg; 0.39 mmol) was mixed with dry methanol (10 ml) and metal sodium (5 mg) was added. The course of the reaction was monitored by reverse TLC (water/THF 1:1). The reaction mixture was then acidified with acetic acid to pH 6 and evaporated at a rotary vacuum evaporator. Water was added to the evaporate and the resulting suspension was drained out and washed with water. The precipitate was dried in exsiccator over phosphorus(V) oxide. The obtained free glucoside 4i (180 mg; 0.28 mmol), 68 %) had m.p. 196.0 0C, [α]D = -46° (c = 0.29). IR spectrum: 1609 (C=C); 1697, 1724 (C=O); 3411 (O-H). 1H NMR spectrum: 0.82 s, 3H; 0.89 s, 3H; 0.93 s, 3H; 1.02 s, 3H; 1.03 s, 3H; 1.20 s, 3H; 1.21 s, 3H (7χCH3); 1.25 t, 3H (J=7.2; -CH2-CH3); 2.14 d, IH (J=18.5; H-22b); 2.45 d, IH (J=I 8.8; H-22a); 2.42-2.52 m, IH (ΣJ=40; H-16β); 2.68 dd, IH (Ji=12.8, J2=2.6; H- 13β); 3.13-3.50 m, 6H (H-3α, H-20, H-5', H-3', H-4', H-2'); 3.75-3.87 m, 2H (H- 6'a,b); 4.10-4.24 m, 2H (0-CH2); 3.79 d, IH (J=7,6; H-I '). MS ESI m/z (%): [For C38H60O9, M+ 660], 683 ([M+Na] +, 60). Elemental analysis for C38H60O9: calculated C 66.06 %, H 9.15 %; found C 66.39 %, H 8.98 %.
Example 8
Preparation of bisghicoside 7e, 7f (method H-3) i) To a suspension of the diol 7a (2.00 g; 3.92 mmol) in dry acetonitrile (25 ml), 2,3,4,6-tetraacetyl-α-D-glucopyranosyl bromide (6.4 g; 15.7 mmol) and mer- cury(II) cyanide (3.0 g; 11.8 mmol) were added and the mixture was then refluxed under a reflux condenser with the exclusion of air moisture. The course of the reaction was monitored by TLC (toluene/ether 6:1). The cooled-down reaction mixture was then bubbled through with moisted hydrogen sulphide, filtered through diatomaceous earth, the filtrate was diluted by ten-fold excess of water and extracted into ethyl acetate. The combined organic extracts were shaken with water three times, dried by magnesium sulphate and the solvents were evaporated on a rotary vacuum evaporator. The evaporate was purified by column chromatography on silica gel, the mobile phase being toluene with gradient diethyl ether. The obtained acetylated bisglucoside 7d (2,50 g; 54 %) had m.p. 102.7 °C, [α]D = +14° (c = 0.28). IR spectrum: 1234 (C-O); 1603 (C=C); 1755 (C=O). 1H NMR spectrum: 0.73 s, 3H; 0.87 s, 3H; 0.89 s, 3H; 0.90 s, 3H; 1.09 s, 3H (5* CH3); 1.99 s, 3H; 2.01 s, 3H; 2.02 s, 3H; 2.02 s, 3H; 2.03 s, 3H; 2.03 s, 3H; 2.04 s, 3H; 2.08 s, 3H (8*CH3COO); 2.38 dt, IH (J1=M-O, J2=4.9; H-16α); 3.58 dd, IH (J1=ILS, J2=3.5; H-13β); 3.07 dd, IH (J1=ILo, J2=4.9; H-3α); 3.51 m, IH (ΣJ=16.8; H-5'); 3.67 m, IH (ΣJ=17.7; H-5'); 3.99 d, IH (J=ILO; H-28a); 4.11 m, 2H (H-6'a,b); 4.20 d, IH (J=I0.7; H-28b); 4.25 m, 2H (H-6'a,b); 4.53 d, IH (J=7.9; H-L); 4.63 d, IH (J=8.2; H-L); 4.89 dd, IH (J]=9.5, J2=7.9; H-3'); 5.03 m, IH (ΣJ=24.0; H- 31); 5.07-5.16 m, 3H (2χ H-2'); 5.17-5.23 m, 2H (2x H-4'); 5.19 bs, 2H (Bn); 7.37 m,
5H (Ph). MS ESI m/z (%): [Pro C60H82O235 M+ 1170], 1193 ([MH-Na]+, 60). Elemental analysis for C60H82O23: calculated C 61.53 % , H 7.06 %; found C 63.86 %, H 7.52 %. ii) The obtained acetylated bisglucoside 7d (2.30 g; 1.97 mmol) was mixed with dry methanol (250 ml) and metal sodium (10 mg) was added into the mixture. The course of the reaction was monitored by reverse TLC (water/THF 1:1). The reaction mixture was then acidified with acetic acid to reach pH 6 and evaporated on a rotary vacuum evaporator. To the evaporate, water was added and the resulting suspension was filtered and washed with water. The precipitate was dried in exsiccator over phosphorus(V) oxide. The obtained bisglucoside 7e (1.36 g; 54 %) had m.p. 186 °C, [α]D = +5° (c = 0.33 ). IR spectrum (measured by the ATR technique): 1034, 1076 (C- O); 1708, 1726 (C=O); 3403 (O-H). 1H NMR spectrum: 0.84 s, 3H; 0.89 s, 3H; 0.93 s, 3H; 1.02 s, 3H; 1.12 s, 3H (5χCH3); 2.39 dt, IH (J1=D-O, J2=3.7; H-16α); 2.71 d, IH (J=9.0; H-13β); 3.17m, IH (H-3α); 3.24-3.34 m, 4H (2χH-5', 2*H-2'); 3.36-3.48 m, 4H (H-3', H-4'); 3.68-3.80 m, 2H (H-6'a,b); 3.84 m, 2H (H-6'a,b); 3.94 d, IH (J=9.8; H-28a); 4.30 d, IH (J=10.0; H-28b); 4.33 d, IH (J=7.6; H-I '); 4.34 d, IH (J=7.6; H- 1') 5.20 bs, 2H (Bn); 7.35 m, 5H (ΣJ=3.2; Ph). 13C NMR spectrum is shown in Table 3. MS ESI m/z (%): [For C44H66O15, M+ 834], 858 ([M+Na] +, 40). Elemental analysis for C44H66O15: calculated C 63.29 %, H 7.97 %; found C 63.44 %, H 7.52 %. ii) The bisglucoside 7e (l.,10 g; 1.32 mmol) was dissolved in the mixture of THF
(10 ml) and methanol (10 ml) and the benzyl group was deprotected in an autoclave at the presence of Pd/C (100 mg; 10%) under hydrogen overpressure (0.6 MPa) while stirring. The course of the reaction was monitored by reverse TLC (water/THF 1 :1). After 24 hours, the autoclave was opened and the reaction mixture was filtered through diatomaceous earth column. The eluate was evaporated on a rotary vacuum evaporator and the evaporate was recrystallized from methanol. The obtained bisglu- cosidic acid 7f (785 mg; 42 %) had m.p. 194 °C, [α]D = +19 (c = 0.31). IR spectrum (measured by the ATR technique): 1033, 1079 (C-O); 1693, 1707 (C=O); 3386 (O-H). 1H NMR spectrum: 0.85 s, 3H; 0.93 s, 3H; 0.96 s, 3H; 1.05 s, 3H; 1.18 s, 3H (5xCH3); 2.32-2.45 m, IH (H-16α); 2.87 dd, IH (J1=I 1.2, J2=2.8; H-13β); 3.11-3.15 m (ΣJ-17.2; H-3α); 3.15-3.22 m, 4H; 3.24-3.30 m, 4H; 3.65 d, 2H (J=4.7; 2xH-6'a); 3.68 d, 2H (J=4.9; 2xH-6'b); 3.85 d, IH (J= 12.4; H-28a); 4.29 d, 2H (J= 8.1; H-I'); 4.31 d, IH (J=13.7; H-28b); 4.32 d, IH (J=7.7; H-I '). MS ESI m/z (%): [Pro C37H60O15, M+ 734], 767 ([IvB-Na]+, 40). Elemental analysis for C37H60O15: calculated
C 59.66 % , H 8.12 %; found C 59.93 %, H 8.01 %.
Example 9 Preparation of 2-deoxygalactoside 4k (method H-4) i) Into a solution of the triterpenic hydroxyderivative 4g (500 mg; 1.0 mmol) in dry acetonitrile (30 ml), tri-Oacetylgalactal (1.2 mmol), molecular sieve 4A (500 mg), lithium bromide (730 mg) and dried cation exchange resin in H+ cycle (900 mg) were added. The reaction mixture was stirred at room temperature for 12 hours. The course of the reaction was monitored by thin-layer chromatography, the mobile phase being hexane: ethyl acetate 2:1. The reaction mixture was then filtered through a diatoma- ceous earth layer and the column was then washed with ethyl acetate. The reaction mixture was diluted with water (50 ml), extracted with ethyl acetate (2x 20 ml) and the organic phase was evaporated on a rotary vacuum evaporator. The evaporate was dis- solved in chloroform (5 ml) and the solution was poured over a short column of silica gel (elution with ethyl acetate). The eluate was evaporated on a rotary vacuum evaporator. The crude product was then separated by column chromatography on silica gel, elution with toluene. The product was then lyophilized from 2-methylpropan-2-ol, white lyophilizate was obtained 4j (360 mg; 47 %) having melting point 100.8 0C, [α]D = +38.9° (c = 0.52). ii) 2-deoxygalactoside 4j (200 mg; 0.26 mmol) was dissolved in dry methanol (300 ml) and catalytic amount of sodium (5 mg) was added into the solution. The course of the reaction was monitored by thin-layer chromatography on reverse phase (mobile phase water/tetrahydrofurane 1:1). The reaction mixture was neutralized with acetic acid and evaporated on a rotary vacuum evaporator. To the evaporate, water (300 ml) was added and the yielded precipitate of the product was filtered off. The filtration cake was washed with water. Obtained was white crystalline 2-deoxyglucoside 4k (161 mg; 97 %) having melting point of 158.0 0C and [α]D = +17.2° (c = 0.51).
Example 10
Preparation of 2-deoxyglucoside 4m (method H-4) i) Into a solution of the triterpenic hydroxyderivative 4d (500 mg; 1.0 mmol) in dry acetonitrile (30 ml), tri-Oacetylglucal (1.2 mmol), molecular sieve 4A (500 mg), lithium bromide (730 mg) and dried cation exchange resin in H+ cycle (900 mg) were added. The reaction mixture was stirred at room temperature for 12 hours. The course of the reaction was monitored by thin-layer chromatography, the mobile phase being hexane:ethyl acetate 2:1. The reaction mixture was then filtered through a diatoma- ceous earth layer, and the column was washed with ethyl acetate. The reaction mixture was diluted with water (50 ml), extracted with ethyl acetate (2x 20 ml) and the organic phase was evaporated on a rotary vacuum evaporator. The evaporate was dissolved in chloroform (5 ml) and the solution was poured over a short column of silica gel (elution with ethyl acetate). The eluate was evaporated on a rotary vacuum evapo- rator. The crude product was then separated by column chromatography on silica gel, eluted with toluene. The product was then lyophilized from 2-methylpropan-2-ol, obtained was white lyophilizate 41 (245 mg; 34 %), melting point 204.1 °C, [α]D = +24.2 (c = 0.43). ii) 2-deoxyglucoside 41 (60 mg; 0.08 mmol) was dissolved in dry methanol (100 ml) and a catalytic amount of sodium (5 mg) was added into the solution. The course of the reaction was monitored by thin-layer chromatography on reverse phase (mobile phase water :tetrahydrofurane 1 : 1). The reaction mixture was neutralized with acetic acid and evaporated on a rotary vacuum evaporator. To the evaporate, water (100 ml) was added and the yielded precipitate of the product was filtered off. The fil- tration cake was washed with water. Obtained was white crystalline 2-deoxyglucoside 4m (39 mg; 74 %) having the melting point of 208.0 0C, [α]D = +14.0 (c = 0.40). 13C NMR spectrum: 15.7, 16.1, 16.5, 16.6, 18.0, 19.7, 19.8, 21.0, 21.6, 24.9, 27.5, 28.3, 28.9, 33.5, 34.7, 37.0, 37.6, 38.2, 38.3, 41.1, 45.1, 45.2, 47.4, 50.9, 52.4, 53.0, 55.4, 62.7, 68.6, 71.2, 72.1, 81.4, 93.1, 174.9, 145.5, 172.7, 208.0. MS m/z (%): [For C3H58O8, M+ 630], 653 ([M+Na]+, 30), 631 ([M+H]+, 30). For C37H58O8 (630.9) calculated: C 70.44 %, H 9.27 %. Found: C 70.58 %, H 9.13 %.
Example 11
Preparation of glycolate 4a (method K-I) i) To a mixture of 21-oxoacid 4 (500 mg; 0.98 mmol) and potassium carbonate
(276 mg; 2.0 mmol) in dichlormethane (10 ml) and acetonitrile (5 ml), benzyl bromoacetate (240 μl; 1.5 mmol) was added and the reaction mixture was stirred at room temperature for 24 h. The course of the reaction was monitored by TLC (tolu- ene/diethyl ether 6:1). The reaction mixture was diluted with ten-fold excess of water and extracted into dichloromethane. The combined organic phases were shaken once with 5% HCl, three times with water, dried with magnesium sulphate and the solvents were evaporated on a rotary vacuum evaporator. The evaporate was purified by column chromatography on silica gel, the mobile phase being toluene. The obtained crude 21-oxoacid benzyl glycolate (509 mg; 79 %) was used in the next step. ii) Into a solution of 21-oxoacid benzyl glycolate (350 mg; 0.5 mmol) in the mixture of tetrahydrofurane (20 ml) and methanol (10 ml), palladium on carbon (75 mg; 10%) and 1,4-cyclohexadiene (473 μl; 5 mmol) were added and the reaction mixture was stirred at room temperature for 20 h. The course of the reaction was monitored using TLC (toluene/diethyl ether 4:1). The reaction mixture was then filtered through diatomaceous earth and the eluate was evaporated on a rotary vacuum evaporator. By the crystallization of the evaporate from the mixture of acetone/water, 21-oxoacid glycolate 4a (272 mg; 90 %) having m.p. 267 - 269 °C, [αJD = -33° (c = 0.39) was obtained. 13C NMR spectrum: 15.9, 16.5, 16.6, 16.8, 18.1, 20.0, 20.1, 21.2, 21.3, 27.7, 29.0, 23.6, 25.1, 27.9, 33.5, 34.9, 37.1, 37.7, 38.5, 41.4, 45.3, 45.3, 47.3, 51.1, 53.1, 55.4, 60.4, 80.8, 146.0, 171.2, 171.7, 172.4, 173.7, 208.0. MS5 m/z (%): [For C34H50O7, M+ 570], 570 (M+, 18), 527 (5), 510 (22), 495 (6), 467 (23), 375 (4), 359 (3), 320 (16), 307 (98), 229 (10), 203 (31), 189 (52). For C34H50O7 (570.4) calculated: 71.55 % C, 8.83 % H; found: 71.52 % C, 8.85 % H.
Example 12
Preparation of glycolate 7d (method K-I) i) To a mixture of pentanoracid 7 (600 mg; 1.2 mmol), silver carbonate (440 mg; 1.6 mmol) in a mixture of chloroform (10 ml) and acetonitrile (7 ml), benzyl bromacetate (260 μl; 1.6 mmol) was added and the reaction mixture was stirred for 28 hours at room temperature. The course of the reaction was monitored by TLC (toluene/diethyl ether 6:1). The reaction mixture was then filtered through diatomaceous earth and the filtrate was worked-up and the product was purified by analogical proce- dure as in the preparation of 21-oxoacid benzyl glycolate. The obtained crude pentanoracid benzyl glycolate (358 mg; 46 %) having m.p. 156-157 °C (methanol), [α]D = +57° (c = 0.31) was used in the next step. ii) Into a solution of pentanoracid benzyl glycolate (300 mg; 0.5 mmol) in a mixture of tetrahydrofurane (10 ml) and methanol (3 ml), palladium on carbon (75 mg; 10%) was added and the reaction mixture was hydrogenated with hydrogen in an autoclave under stirring at room temperature for 5 h. The course of the reaction was monitored by TLC (chloroform). The reaction mixture was then filtered through dia- tomaceous earth and the eluate was evaporated on a rotary vacuum evaporator. By crystallization of the evaporate from the mixture acetone/water, glycolate 7d (215 mg; 83 %) having m.p. 230 - 230 °C, [α]D = 66° (c = 0.23) was obtained. 13C NMR spectrum: 16.0, 16.2, 16.5, 16.7, 18.1, 19.7, 20.7, 21.3, 21.8, 23.6, 26.5, 27.1, 27.9, 34.0, 37.1, 37.8, 38.5, 41.0, 46.7, 50.5, 50.4, 55.4, 61.0, 63.2, 80.6, 170.2, 170.7, 171.0, 171.2, 210.5. MS, m/z (%): [For C31H46O9, M+ 562], 562 (M+, 1), 516 (36), 502 (38), 487 (18), 459 (19), 415 (10), 339 (8), 313 (54), 223 (11), 204 (15), 189 (70). For C31H49O9 (562.3) calculated: 66.17 % C, 8.24 % H; found: 66.24 % C, 8.31 % H.
Example 13
Preparation of quarternary ammonium salt 2f (method K-2) i) To a suspension of betulinic acid 2 (1.37 g; 3 mmol) in a mixture of di- chloromethane (15 ml) and acetonitrile (1 ml), potassium carbonate (0.42 g; 3 mmol) and 1,2-dibromoethane (550 ul; 4.5 mmol) were added and the reaction mixture was stirred at room temperature. The course of the reaction was monitored by TLC (toluene/ether 6:1). When all the reagent was consumed, the base was removed by filtration, the mixture was diluted with ten-fold excess of water and extracted into ethyl acetate. Combined organic phases were shaken three times with 5% HCl, three times with water, dried with magnesium sulphate and the solvents were evaporated on a ro- tary vacuum evaporator. The evaporate was purified by column chromatography on silica gel (ethyl acetate gradient in hexane). The obtained 2'-bromoethyl betulinate (480 mg; 28 %) had m.p. 184 0C, [α]D = +7° (c = 0.24). ii) 2'-bromoethyl betulinate (200 mg; 0.35 mmol) was dissolved in DMF (5 ml). To the solution, trimethylamine (0.5 ml; 5.67 mmol) was added, the reaction ves- sel was sealed and left at 60 0C for 1 h. After cooling, the reaction mixture was diluted with ten-fold excess of water and extracted into ethyl acetate. Combined organic phases were shaken three times with 5% HCl, three times with water, dried with magnesium sulphate and the solvents were evaporated on a rotary vacuum evaporator. The evaporate was purified by column chromatography on silica gel (methanol gradient in chloroform). The obtained quarternary ammonium salt 2f (163 mg; 75 %) had m.p. 155 - 156 0C, [α]D = +22° (c = 0.40). 13C NMR spectrum: 15.I5 16.1, 16.6, 16.7, 19.3, 19.5, 21.9, 26.6, 27.9, 28.6, 30.8, 31.3, 32.7, 35.4, 37.5, 38.2, 39.3, 39.8, 39.9, 41.8, 43.4, 50.5, 51.8, 54.4, 56.6, 57.7, 58.4, 59.5, 65.9, 78.7, 79.1, 79.4, 79.5, 110.5, 128.1, 137.3, 151.2, 176.1. Elemental analysis for C35H60BrNO3: calculated C 67.50 % , H 9.71 %; found C 67.46 %, H 9.68 %.
Example 14
Preparation of quarternary ammonium salt 2g (method K-2) 2'-bromoethyl betulinate prepared in Example 12 (285 mg; 0.46 mmol) was dissolved in DMF (5 ml), pyridine (1 ml; 9.49 mmol) was added to the solution, the reaction vessel was sealed and left at 60 °C for 4 days. After cooling, the reaction mixture was diluted with ten-fold excess of water and extracted into ethyl acetate. Combined organic phases were shaken three times with 5% HCl, three times with water, dried with magnesium sulphate and the solvents were evaporated on a rotary vacuum evaporator. The evaporate was purified by column chromatography on silica gel (methanol gradient in chloroform). The obtained quarternary ammonium salt 2g (527 mg; 86 %) had m.p. 186 - 187 °C, [α]D = +45° (c = 0.39). 13C NMR spectrum: 15.0, 16.1, 16.7, 16.7, 19.4, 19.4, 21.9, 26.6, 28.0, 28.6, 30.8, 31.4, 32.7, 35.5, 37.5, 38.2, 39.5, 39.9, 40.0, 41.8, 43.4, 50.6, 51.8, 56.7, 57.9, 61.5, 63.6, 79.5, 79.5, 110.5, 129.7, 146.6, 147.7, 151.4, 176.3. Elemental analysis for C37H56BrNO3: calculated C 69.14 % , H 8.78 %; found C 69.18 %, H 8.76 %.
Example 15 Preparation of quarternary ammonium salt 4o (method K-2) i) Into a suspension of acid 4 (5.O g; 10 mmol) in the mixture of dichloro- methane (150 ml) and acetonitrile (5 ml), potassium carbonate (2 g; 14.2 mmol) and 1,2-dibromoethane (1.65 ml; 13.5 mmol) were added and the reaction mixture was stirred at room temperature. The course of the reaction was monitored by TLC (tolu- ene/ether 6:1). After all the reactant was consumed, the base was removed by filtration, the mixture was diluted with ten-fold excess of water and extracted into ethyl acetate. Combined organic phases were shaken three times with 5% HCl, three times with water, dried by magnesium sulphate and the solvents were evaporated on a rotary vacuum evaporator. The evaporate was purified by column chromatography on silica gel (ethyl acetate gradient in hexane). The obtained 2'-bromoethylester of acid 4 (2.3 mg; 37 %) had m.p. 210 °C, [α]D = 23° (c = 0.35). ii) The obtained 2'-bromoethylester of acid 4 (285 mg; 0.46 mmol) was dissolved in DMF (5 ml). To the solution, triethylamine (0.5 ml; 3.39 mmol) was added, the reaction vessel was sealed and left at 60 °C for 4 days. After cooling down, the reaction mixture was diluted with ten-fold excess of water and extracted into ethyl acetate. Combined organic phases were shaken three times with 5% HCl, three times with water, dried with magnesium sulphate and the solvents were evaporated on a rotary vacuum evaporator. The evaporate was purified by column chromatography on silica gel (methanol gradient in chloroform). The obtained quarternary ammonium ester 4o (68 mg; 19 %) had m.p. 183 °C, [α]D = +15° (c = 0.31). 13C NMR spectrum: 16.4, 16.8, 17.2, 17.2, 18.7, 20.1, 21.4, 21.8, 24.2, 25.7, 28.3, 29.6, 29.8, 33.9, 35.5, 37.8, 38.4, 42.0, 45.9, 51.7, 53.9, 56.1, 65.3, 78.0, 78.3, 78.6, 81.9, 146.5, 172.5, 174.6, 209.1. Elemental analysis for C40H66BrNO5: calculated C 66.65 % , H 9.23 %; found C 66.66 %, H 9.26 %.
Example 16
Preparation of quarternary ammonium salt 4p (method K-2)
2'-bromoethylester of acid 4 obtained in Example 14 (285 mg; 0.46 mmol) was dissolved in DMF (5 ml). To the solution, triethanolamine (500 mg; 4.7 mmol) was added, the reaction vessel was sealed and left at 60 0C for 10 days. After cooling down, the reaction mixture was diluted with ten-fold excess of water and extracted into ethyl acetate. Combined organic phases were shaken three times with 5% HCl, three times with water, dried with magnesium sulphate and the solvents were evapo- rated on a rotary vacuum evaporator. The evaporate was purified by column chromatography on silica gel (methanol gradient in chloroform). The obtained quarternary ammonium ester 4p (134 mg; 41 %) had m.p. 162 - 163 °C, [α]D = +28° (c = 0.13). 13C NMR spectrum 16.5, 17.0, 17.3, 17.4, 19.2, 20.3, 20.6, 21.1, 22.4, 2.6, 26.4, 28.4, 28.8, 3.2, 34.5, 36.0, 38.3, 38.9, 39.6, 42.6, 46.0, 46.5, 46.8, 52.3, 54.3, 54.5, 56.7, 57.9, 60.8, 64.6, 79.5, 146.8, 172.8, 14.4, 15.5, 209.7. Elemental analysis for C40H66BrNO8: calculated C 62.49 % , H 8.65 %; found C 62.52 %, H 8.62 %.
Example 17
Preparation of hemiglutarate 2i (method H-5) Into a solution of methyl betulinate (2h) (500 mg; 0.94 mmol) in 2,4,6- trimethylpyridine (10 ml), glutaric anhydride (1.15 g; 10 mmol) and DMAP (50 mg; 0.4 mmol) were added and the reaction mixture was refluxed while stirring for 8 hours. The course of the reaction was monitored by TLC (toluene/diethyl ether 2:1). The reaction mixture was then cooled down, diluted with ten-fold excess of water and extracted into ethyl acetate. Combined organic phases were shaken three times with 5% HCl, three times with water, dried with magnesium sulphate and the solvents were evaporated on a rotary vacuum evaporator. The evaporate was purified by column chromatography on silica gel by gradient elution from 8% ethyl acetate in hexa- ne to 25% ethyl acetate in hexane. By crystallization from 2,2,4-trimethylpentane he- miglutarate 2i (386 mg; 62 %) was obtained in the form of white crystals having m.p. 165 °C, [α]D +17.5 (c 0.32). IR spectrum: 1230 (C-O), 1641 (C=C), 1716 (C=O), 2430 - 3500 (COOH), 3521 (O-H). 1H NMR spectrum: 0.83 s, 3H; 0.83 s, 3H; 0.84 s, 3H; 0.91 s, 3H; 0.96s, 3H; 1.69 s, 3H, (6χCH3); 1.87-1.90 m, 2H; 1.92-2.00 pentet, 2H (J=7.2 Hz, H-33); 2.16-2.25 m, 2H; 2.37-2.41 1, 2H (J=7.3 Hz, H-32); 2.41-2.45 t, 2H (J=7.3 Hz, H-34); 3.00 m, IH; 3.67 s, 3H (OCH3); 4.46-4.50 m, IH (H-3α); 4.60 s, IH (H-29 pro-E); 4.73 s, IH (H-29 pro-Z). 13C NMR spectrum: 14.68, 15.94, 16.16, 16.54, 18.18, 19.34, 20.00, 20.89, 23.73, 25.46, 27.99, 29.66, 30.59, 32.16, 32.93, 33.64, 34.24, 36.96, 37.10, 37.82, 38.24, 38.36, 40.68, 42.38, 46.99, 49.45, 50.44, 51.25, 55.41, 56.55, 81.10, 109.61, 150.54, 172.62, 176.68, 178.27. MS, m/z (%): [Pro C36H56O6, M+ 584], 584 (M+, 3), 569 (2), 552 (1), 524 (3), 509 (1), 466 (1), 452 (15), 437 (7), 409 (5), 393 (4), 273 (3), 262 (12), 249 (6), 233 (5), 215 (6), 203 (14), 189 (37). Elemental analysis for C36H56O6: calculated C 73.93 %, H 9.65 %; found C 73.79 %, H 9.81 %.
Example 18
Preparation of galactopyranosyl ester 21 (method K-3) i) Into a solution of betulinic acid (2) (1.00 g; 2.2 mmol) in a mixture of acetone (40 ml) and acetonitrile (20 ml), potassium carbonate (350 mg; 2.5 mmol) and 2,3,4,6-tetraacetyl-α-D-galactopyranosyl bromide (1.60 g; 3.6 mmol) were added. The course of the reaction was monitored by TLC (toluene/ether 10:1). When all the starting material was consumed, the base potassium carbonate was removed by filtration, the mixture was diluted with ten-fold excess of water and extracted into ethyl acetate. Combined organic phases were shaken once with 5% HCl, three times with water, dried with magnesium sulphate and the solvents were evaporated on a rotary vacuum evaporator. The evaporate was purified by column chromatography on silica gel (ethyl acetate/hexane 1 :4). The obtained 2',3',4',6'-tetraacetyl-α-D-galactopyranosyl betuli- nate 2k (1.60 g; 93 %) had m.p. 189-190 0C (2,2,4-trimethylpentane), [α]D +3.3° (c 0.46, ethanol). IR spectrum: 1641 (C=C), 1752 (C=O), 3612 (O-H). 1H NMR spectrum: 0.75 s, 3H; 0.82 s, 3H; 0.90 s, 3H; 0.92 s, 3H; 0.96 s, 3H; 1.68 s, 3H; (6x CH3); 2.00 s, 3H; 2.03 s, 3H; 2.04 s, 3H; 2.17 s, 3H; (4x CH3COO); 2.95 td, IH (Ji=I 1.2, J2=4.9; H-19β); 3.18 dd, IH (J1=I 1.2, J2=4.6; H-3α); 4.02-4.06 m, IH ens'); 4.08-4.18 m, 2H (H-6'a, H-6'b); 4.60 bs, IH (H-29 pro-E); A.I A d, IH (J=IJ; H- 29 pro-Z); 5.11 dd, IH (J1=ICS, J2=3.4; H-3'); 5.37 dd, IH (J1=IO^, J2=8.3; H-2'); 5.43 d, IH (J=3.4; H-4'); 5.65 d, IH (J=8.5; H-I'). MS, m/z (%): [For C44H66O12, M+ 786], 786 (M+, 0.5), 696 (1), 579 (1), 455 (8), 437 (7), 411 (20), 393 (11), 331 (100), 203 (6), 189 (12). Elemental analysis: for C44H66O12 (786.5) calculated: 67.15 % C, 8.45 % H; found: 67.19 % C, 8.51 % H. ii) 2',3',4',6'-tetraacetyl-α-D-galactopyranosyl betulinate 2k (1.00 g; 1.3 mmol) was dissolved in dry methanol (40 ml) and a catalytic amount of sodium (5 mg) was added into the solution. The course of the reaction was monitored by thin-layer chromatography on reverse phase (mobile phase wateπtetrahydrofurane 1:1). After one hour, the reaction mixture was neutralized with acetic acid and evaporated on a rotary vacuum evaporator. To the evaporate, water (100 ml) was added and the yielded precipitate of the product was filtered off. The filtration cake was washed with water. Obtained was galactopyranosyl ester 21 in the form of white powder (685 mg; 86 %), m. p. 238-240 °C (chloroform), [α]D 0° (c 0.39, ethanol). IR spectrum (KBr): 1641 (C=C), 1740 (C=O), 3200-3600 (O-H). 1H NMR spectrum: 0.75 s, 3H; 0.82 s, 3H; 0.93 s, 3H; 0.95 s, 3H; 0.98 s, 3H; 1.69 s, 3H; (6x CH3); 1.88-2.04 m, 2H (H-21β, H- 22β); 2.23-2.37 m, 2H (H-13β, H-16β); 3.00 td, IH (Ji=I 0.4, J2=4.6; H-19β); 3.16 t, IH (J=7.8; H-3α); 3.57 dd, IH (JΪ=9.5, J2=3.2; H-3'); 3.62-3.82 m, 4H (H-2', H-5', H- 6'a, H-6'b); 3.97 d, IH (J=2.9; H-4'); 4.60 s, IH (H-29 pro-E); 4.73 s, IH (H-29 pro- Z); 5.46 d, IH (J=8.1; H-I'). MS, m/z (%): [For C36H58O8, M+ 618], 618 (M+, not found), 592 (1), 531 (1), 456 (18), 438 (17), 412 (10), 395 (11), 327 (6), 248 (47), 207 (53), 189 (100). Elemental analysis: for C36H58O8 (618.4) calculated: 67.87 % C, 9.45 % H; found: 67.79 % C, 9.50 % H. Example 19
Preparation of 3',3'-dimethylhemigIutarate 4q (method H-6)
Into a solution of ethyl ester 4g (500 mg; 0.99 mmol) in 2,4,6- trimethylpyridine (10 ml), 3,3-dimethylglutaric anhydride (600 mg; 2.4 mmol) and DMAP (50 mg; 0.4 mmol) were added and the reaction mixture was refluxed while stirring for 8 hours. The course of the reaction was monitored by TLC (toluene/diethyl ether 5:1). The reaction mixture was then cooled down, diluted with ten-fold excess of water and extracted into ethyl acetate. Combined organic phases were shaken three times with 5% HCl, three times with water, dried with magnesium sulphate and the solvents were evaporated on a rotary vacuum evaporator. The evaporate was purified by column chromatography on silica gel by gradient elution from 8% ethyl acetate in hexane to 25% ethyl acetate in hexane. The chromatographically uniform dimethyl hemiglutarate 4q was lyophilized from tert-butylalcohol (375 mg; 59 %). 13C NMR spectrum: 14.15, 15.91, 16.62, 16.76, 18.11, 19.93, 20.16, 21.25, 23.68, 23.83, 24.03, 25.10, 27.63, 29.08, 30.80, 32.70, 33.51, 33.84, 34.79, 35.41, 37.12, 37.67, 37.81, 38.53, 41.29, 45.12, 45.52, 47.61, 50.99, 52.98, 55.43, 61.01, 81.24, 145.67, 171.82, 172.41, 174.32, 175.87, 207.36.
Example 20 Preparation of 3 ',3 '-dimethylhemisuccinate 4t (method H-7*) i) Into a solution of benzyl 3β-hydroxy-21-oxolup-18-en-28-oate (500 mg; 0.89 mmol) in 2,4,6-trimethylpyridine (10 ml), 2,2-dimethylsuccinic anhydride (500 mg; 2.3 mmol) and DMAP (50 mg; 0.4 mmol) were added and the reaction mixture was refluxed while stirring for 8 hours. The course of the reaction was monitored by TLC (toluene/diethyl ether 5:1). The reaction mixture was then cooled down, diluted with ten-fold excess of water and extracted into ethyl acetate. Combined organic phases were shaken three times with 5% HCl, three times with water, dried with magnesium sulphate and the solvents were evaporated on a rotary vacuum evaporator. The evaporate was purified by column chromatography on silica gel by gradient elution from 8% ethyl acetate in hexane to 25% ethyl acetate in hexane. The chromatographically uniform benzyl 3β-(3',3'-dimethylsuccinyloxy)-21-oxolup-18-en-28-oate was lyophilized from tert-butylalcohol (380 mg; 55 %). 13C NMR spectrum: 15.85, 16.43, 16.50, 16.73, 18.04, 19.89, 20.25, 21.04, 23.52, 25.01, 25.1O5 25.59, 27.54, 27.86, 28.87, 33.43, 34.77, 37.05, 37.69, 38.53, 40.44, 40.74, 41.19, 44.67, 45.05, 45.16, 47.41, 50.96, 52.91, 55.41, 66.52, 81.32, 128.34, 128.58, 135.80, 145.62, 170.92, 171.84,
173.89, 176.24, 207.30. ii) Into a solution of benzyl 3β-(3',3'-dimethylhemisukcinyloxy)-21-oxolup-18- en-28-oate (380 mg; 0.55 mmol) m ethanol (10 ml) and tetrahydrofurane (THF) (10 ml), cyklohexadiene (200 μl; 2.14 mmol) and Pd/C (150 mg; 10%) were added and the reaction mixture was stirred for 48 hours at laboratory temperature. The course of the reaction was monitored by TLC (toluene/diethyl ether 5:1). The reaction mixture was then filteres through a paper filter and the solvents were evaporated on a rotary vacuum evaporator. The dimethyl succinate 4t was lyophilized from tert-butylalcohol (312 mg; 95 %). 13C NMR spectrum: 15.85, 16.43, 16.50, 16.73, 18.04, 19.89, 20.25, 21.04, 23.52, 25.01, 25.10, 25.59, 27.54, 27.86, 28.87, 33.43, 34.77, 37.05, 37.69, 38.53, 40.44, 40.74, 41.19, 44.67, 45.05, 45.16, 47.41, 50.96, 52.91, 55.41, 81.32, 170.92, 171.84, 173.89, 176.24, 207.30.
Example 21
Preparation of hemitetrahydrophthalate 2m (method H-8)
Into a solution of methyl betulinate (2h) (500 mg; 0.94 mmol) in 2,4,6- trimethylpyridine (10 ml),
Figure imgf000025_0001
anhydride (760 mg; 5 mmol) and DMAP (50 mg; 0.4 mmol) were added and the reaction mixture was refluxed whi- Ie stirring for 8 hours. The course of the reaction was monitored by TLC (toluene/diethyl ether 5:1). The reaction mixture was then cooled down, diluted with tenfold excess of water and extracted into ethyl acetate. Combined organic phases were shaken three times with 5% HCl, three times with water, dried with magnesium sulphate and the solvents were evaporated on a rotary vacuum evaporator. The evaporate was purified by column chromatography on silica gel by gradient elution from 8% ethyl acetate in hexane to 25% ethyl acetate in hexane. By crystallization from iso- octane, hemitetrahydrophthalate 2m (510 mg; 78 %) was obtained in the form of white crystals having m.p. 224 0C, [α]D+9.5 (c 0.32). IR spectrum: 1235 (C-O), 1641 (C=C), 1716 (C-O), 2250 - 3490 (COOH), 3512 (O-H). 1H NMR spectrum: 0.80 s, 3H; 0.81 s, 3H; 0.83 s, 3H; 0.91 s, 3H; 0.96 s, 3H; 1.69 s, 3H, (6xCH3); 1.84-1.93 m, 2H; 2.18-2.25 m, 2H; 2.33-2.66 m, 4H (H-33, H-36); 3.00 m, IH; 3.07-3.15 m, 2H (H-32, H-37); 3.67 s, 3H (OCH3); 4.47-4.53 m, IH (H-3α); 4.60 s, IH (H-29 pro-E); 4.73 s, IH (H-29 pro-Z); 5.69 d, 2H (J=7.6 Hz, H-34, H-35). 13C NMR spectrum: 14.69, 15.94, 16.11, 16.51, 18.14, 19.33, 20.89, 23.51, 25.31, 25.45, 26.34, 27.80, 29.65, 30.58, 32.15, 34.22, 36.94, 37.08, 37.86, 38.23, 38.36, 39.67, 39.90, 40.68, 42.38,
46.98, 49.44, 50.40, 51.24, 55.43, 56.54, 81.61, 109.61, 125.11, 125.39, 150.54, 172.81, 176.66, 178.84. MS, m/z (%): [Pro C39H58O6, M+ 622], 622 (M+, 4), 607 (2), 579 (1), 562 (5), 452 (52), 437 (17), 409 (13), 393 (15), 273 (6), 262 (25), 249 (14), 233 (7), 215 (13), 203 (41), 189 (100). Elemental analysis: for C39H58O6 (622) calculated: C 75.20 %, H 9.39 %; found: C 75.08 %, H 9.48 %.
Example 22
Preparation of hemidiglycolate 4x (method H-9) Into a solution of ethyl ester 4g (500 mg; 0.99 mmol) in 2,4,6- trimethylpyridine (10 ml), diglycolic anhydride (500 mg; 2.3 mmol) and DMAP (50 mg; 0.4 mmol) were added and the reaction mixture was refluxed while stirring for 8 hours. The course of the reaction was monitored by TLC (toluene/diethyl ether 5:1). The reaction mixture was then cooled down, diluted with ten-fold excess of water and extracted into ethyl acetate. Combined organic phases were shaken three times with 5% HCl, three times with water, dried with magnesium sulphate and the solvents were evaporated on a rotary vacuum evaporator. The evaporate was purified by column chromatography on silica gel by gradient elution from 8% ethyl acetate in hexa- ne to 25% ethyl acetate in hexane. The chromatographically uniform diglycolate 4x was lyophilized from tert-butylalcohol (406 mg; 66 %). 13C NMR spectrum: 14.16, 15.92, 16.51, 16.62, 16.77, 18.12, 19.98, 20.15, 21.30, 23.57, 25.13, 26.38, 27.48, 27.62, 28.04, 29.09, 29.68, 33.50, 34.77, 37.09, 37.86, 38.51, 41.29, 45.10, 47.61, 51.01, 52.96, 55.36, 61.05, 145.66, 171.66, 172.58, 174.27, 175.43, 207.27.
b) Preparation of inclusion compound
Method A: In a mixture of water (26.0 ml), sodium hydrogencarbonate solution (5.0 ml; saturated solution) and ethanol (7.0 ml; 99%), 2-hydroxypropyl-γ- cyklodextrin (10.0 g) is dissolved at the temperature of 50 0C under vigorous stirring. Into the resulting colourless, viscous solution, soluble triterpene derivative (1.50 g) is added at once and the mixture is again vigorously stirred at the temperature of 50 °C. 20 to 40 min of stirring is usually necessary for a complete dissolution. After the triterpenoid is completely dissolved, the resulting clear solution is cooled to room temperature, filtered with a syringe filter (hydrophilic, pore size 0.22 μm) in order to be sterile and is placed in a refrigerator. The obtained solution can be stored in a freezer at - 20 °C until further use without any perceptible decomposition.
Method B: In a mixture of water (14.0 ml) and propylene glycol (6.0 ml), 2- hydroxypropyl-γ-cyklodextrin (7.00 g) is dissolved at the temperature of 50 °C under vigorous stirring. Into the resulting colourless, viscous solution, soluble triterpene derivate (1.00 g) is added at once and is again vigorously stirred at the temperature of
50 °C. 20 to 40 min of stirring is usually necessary for a complete dissolution. After the triterpenoid is completely dissolved, the resulting clear solution is cooled to room temperature, filtered with a syringe filter (hydrophilic, pore size 0.22 μm) in order to be sterile and is placed in a refrigerator. The obtained solution can be stored in a freezer at - 20 °C until further use without any perceptible decomposition.
Determination of bioavailability and pharmacokinetic profile at oral administration of the compounds to laboratory mice Soluble cyclodextrin formulations of terpenoid compounds, prepared in accordance with the aforementioned methods A or B, were administered without dilution to outbred mice CD-I intragastrically (200 μl in a single dose) as aqueous solutions by injection syringe equipped with a gastric tube. Insoluble compounds were administered intragastrically as well (200 μl in a single dose), but in the form of aqueous sus- pensions in 0.5-1% carboxymethyl cellulose. In time intervals 2, 4, 6, 8, 12 and 24 h, blood was taken from the mice, the blood was centrifuged and the obtained plasma was subsequently analysed by HPLC-ESI MS technique.
Analytic determination of the concentration of dissolved triterpenoids in the ap- plication form and in plasma samples
HPLC-ESI MS technique was used or the determination of the concentration of dissolved triterpenoids. The samples were measured in one analytical batch with calibration solutions and blind control. The sample for the measurement was prepared from 50 μl of aqueous solution containing the inclusion compound by dilution with metha- nol to the volume of 10 ml. Subsequently, 10 μl of the sample solution after the first dilution is further diluted to 1 ml by the mobile phase. The blind control was obtained from 50 μl of pre-prepared aqueous solution of 2-hydroxypropyl-γ-cyklodextrin by dilution with methanol to 10 ml. Subsequently, 10 μl of the blind control solution after the first dilution is further diluted to 1 ml by methanol. Stock solutions of standards
(concentration 0.2 mg/ml) were prepared by weighing 2.00 mg of analyte to 10 ml graduated flask and dissolution in methanol. The calibration samples were then prepared by dilution of the stock solution with mobile phase (0.4 μg/ml resp. 4 μg/ml). The analysis was carried out at ODS Hypersil 125 x 2.1 mm, 5um, SN
0745415X, Thermo EC column, ODS 4.0 x 3.0 mm precolumn, Phenomenex, mobile phase A - IOO mmol/L aqueous solution of ammonium formate, pH is adjusted to 5 by formic acid, B - 100 mmol/L methanolic solution of ammonium formate, column temperature: 25 0C, linear gradient or isocratic elution, injected volume 30 μl. The con- centration was determined by comparison with standard and calculated to the original solution containing the inclusion compound.
The pharmacokinetic profiles of selected derivatives at oral administration to mice (compounds 2b, 3, 3b, 5a, 5f, 6a, 8a, 4v, 4i, 2i, 4t were administered as cyclodex- trin formulations, compounds 5c, 5d, 6, 7, 8 as carboxymethyl cellulose suspensions) are shown in Fig. 1 to 12. The results prove oral availability of the soluble cyclodex- trin terpenoid formulations, but not of the insoluble suspensions.
Table 1 : Examples of solubility of biologically active triterpenoids (n=concentration lower than the detection threshold, i.e. 1 ng/ml; months means two or more months)
Figure imgf000029_0001
Figure imgf000030_0001
CH2CH3 CH2CH3 H
CH3
R2 = CH3 R2 = CH3
Figure imgf000031_0001
= CH2CH3 CH2CH3 R2 = CH2CH3 R2 = CH2CH3 R2 = CH2CH3 R2 = CH2CH3 R2 = CH3 = CH3
R2 = CH2CH3 = CH2CH3 = CH3 = H R2 = H = CH3
Figure imgf000031_0002
CH2CH3 = CH2C6H5 = H p-D-glucosyl, R2 = CH2C6H5 CH2C6H5
Figure imgf000032_0001
8, R1 = R2 = H
8a, R1 = CO(CH2)2CO2H, R2 = H

Claims

1. A method of preparation of a soluble formulation of water-insoluble pentacyclic and tetracyclic terpenoids, characterized in that the water-insoluble terpenoid having a free carboxylic, hydroxy or amino functional group is derivatized on this functional group with a substituent selected from the group comprising a) substituents of general formula Xa bound to the hydroxy group of the terpenoid, wherein Xa is -OC-R-COOH, wherein R is linear or branched Ci to C8 alkylene, linear or branched C3 to C8 oxaalkylene, linear or branched C1 to C8 alkenylene, C6 cycloalkylene, C6 cycloalkenylene, C6 arylene unsubstituted or substituted with halogen, hydroxyl or amino group: terpenoid / derivatization terpenoid / moiety
Figure imgf000033_0001
b) substituents of general formula Xa bound to the amino group of the terpenoid, wherein Xa is -OC-R-COOH, wherein R is linear or branched C1 to C8 al- kylene, linear or branched C3 to C8 oxaalkylene, linear or branched C1 to Cg alkenylene, C6 cycloalkylene, C6 cycloalkenylene, C6 arylene unsubstituted or substituted with halogen, hydroxyl or amino group:
terpenoid moiety
Figure imgf000033_0002
c) quarternary ammonium substituents of general formula Xb bound to the car- boxy group of the terpenoid, wherein Xb is -(CH2)HN+R3Y", wherein n is 2-8, R is linear or branched C1 to C8 alkyl, optionally substituted with -OH, -NH2 or halogen, and Y" is anion selected from the group comprising halogenide, sulphate, hydrogensulphate and triflate:
terpenoid moiety
Figure imgf000033_0003
d) quarternary ammonium substituents of general formula Xc bound to the car- boxy group of the terpenoid, wherein Xc je -(CH2)nR+Y", wherein n is 2-8, R+ is protonated nitrogen-containing heterocycle containing 1-2 nitrogen atoms and 4-9 carbon atoms and containing at least one aromatic cycle and Y" is anion selected from the group comprising halogenide, sulphate, hydrogensulphate and triflate:
terpenoid moiety
Figure imgf000034_0001
e) substituents of general formula Xd bound to the carboxy group of the terpenoid, wherein Xd represents -R-COOH, wherein R is linear or branched C1 to C4 alkylene, linear or branched C1 to C4 alkenylene, C6 arylene unsubstituted or substituted with halogen, hydroxy or amino group: terpenoid / derivatization terpenoid /
Figure imgf000034_0002
f) glycosylic substituents Xe bound by α or β glycosidic bond to the carboxy group of the terpenoid, wherein Xe is selected from the group comprising glu- cosyl, galactosyl, arabinosyl, rhamnosyl, lactosyl, cellobiosyl, maltosyl and the 2-deoxyanalogues thereof:
terpenoid moiety
Figure imgf000034_0003
g) glycosylic substituents Xe bound by α or β glycosidic bond to the hydroxy group of the terpenoid, wherein Xe is selected from the group comprising glu- cosyl, galactosyl, arabinosyl, rhamnosyl, lactosyl, cellobiosyl, maltosyl and the 2-deoxyanalogues thereof: terpenoid / derivatization terpenoid /
Figure imgf000034_0004
and subsequently, the prepared derivative is dissolved in a solution containing water, a cyclodextrin and optionally pharmaceutically acceptable auxiliary substances, forming an inclusion derivative with the cyclodextrin.
2. The method according to claim 1, characterized in that the substituents of general formula Xa are selected from the group comprising succinate, glutarate, 3 ',3'- dimethylglutarate, 3',3'-dimethylsuccinate, tetrahydrophthalate, diglycolate or phtha- late.
3. The method according to claim 1, characterized in that the substituents of general formula Xb are choline esters, wherein n=2, R=CH3.
4. The method according to claim 1, characterized in that the substituents of general formula Xc are pyridinium salts, wherein n=2, R+=PyH+, Y "=Br".
5. The method according to claim 1, characterized in that the substituents of general formula Xd are glycolates, wherein R=CH2.
6. The method according to claim 1, characterized in that the substituents of general formula Xe are selected from the group comprising glucosyl, galactosyl, lactosyl and the 2-deoxyanalogues thereof.
7. The method according to any of claims 1 to 6, characterized in that the cyclodextrin is selected from the group comprising native or substituted β-cyclodextrins and γ- cyclodextrins.
8. The method according to any of claims 1 to 7, characterized in that the auxiliary substances are biocompatible organic solvents and/or compounds facilitating the formation of inclusion complexes.
9. The method according to claim 8, characterized in that the biocompatible organic solvents are ethanol or propylene glycol.
10. The method according to claim 8, characterized in that the compounds facilitating the formation of inclusion complexes are alkali carbonates or hydrogen carbonates.
11. A soluble formulation of a pentacyclic or tetracyclic triterpenoid, containing an inclusion complex of the pentacyclic or tetracyclic terpenoid having its carboxy, hydroxy or amino group derivatized with a substituent selected from the group comprising: a) substituents of general formula Xa bound to the hydroxy group of -tϊiΦtsrpe*^" ' noid, wherein Xa is -OC-R-COOH, wherein Xa is -OC-R-COOH, wherein R is linear or branched C1 to C8 alkylene, linear or branched C3 to C8 oxaalkylene, linear or branched C1 to C8 alkenylene, C6 cycloalkylene, C6 cycloalkenylene, C6 arylene unsubstituted or substituted with halogen, hydroxyl or amino group; b) substituents of general formula Xa bound to the amino group of the terpenoid, wherein Xa is -OC-R-COOH, wherein R is linear or branched C1 to C8 alkylene, linear or branched C3 to C8 oxaalkylene, linear or branched C1 to C8 alkenylene, C6 cycloalkylene, C6 cycloalkenylene, C6 arylene unsubstituted or substituted with halogen, hydroxyl or amino group; c) quarternary ammonium substituents of general formula Xb bound to the car- boxy group of the terpenoid, wherein Xb is -(CH2)HN+R3Y", wherein n is 2-8, R is linear or branched C1 to C8 alkyl, optionally substituted with -OH, -NH2 or halogen, and Y' is anion selected from the group comprising halogenide, sul- phate, hydrogensulphate and triflate; d) quarternary ammonium substituents of general formula Xc bound to the car- boxy group of the terpenoid, wherein X0Je -(CH2)nR+Y\ wherein n is 2-8, R+ is protonated nitrogen-containing heterocycle containing 1-2 nitrogen atoms and 4-9 carbon atoms and containing at least one aromatic cycle and Y" is anion se- lected from the group comprising halogenide, sulphate, hydrogensulphate and triflate; e) substituents of general formula Xd bound to the carboxy group of the terpenoid, wherein Xd represents -R-COOH, wherein R is linear or branched Cj to C4 alkylene, linear or branched C1 to C4 alkenylene, C6 arylene unsubstituted or substituted with halogen, hydroxy or amino group; f) glycosylic substituents Xe bound by α or β glycosidic bound to the carboxy group of the terpenoid, wherein Xe is selected from the group comprising glu- cosyl, galactosyl, arabinosyl, rhamnosyl, lactosyl, cellobiosyl, maltosyl and the 2-deoxyanalogues thereof; g) glycosylic substituents Xe bound by α or β glycosidic bound to the hydroxy group of the terpenoid, wherein Xe is selected from the group comprising glu- cosyl, galactosyl, arabinosyl, rhamnosyl, lactosyl, cellobiosyl, maltosyl and the 2-deoxyanalogues thereof, with a cyclodextrin, and optionally water and pharmaceutically acceptable auxiliary substances.
12. The soluble formulation according to claim 11, characterized in that the substitu- ents of general formula Xa are selected from the group comprising succinate, glutarate,
3',3'-dimethylglutarate, 3',3'-dimethylsuccinate, tetrahydrophthalate, diglycolate or phthalate.
13. The soluble formulation according to claim 11, characterized in that the substitu- ents of general formula Xb are choline esters, wherein n=2, R=CH3.
14. The soluble formulation according to claim 11, characterized in that the substitu- ents of general formula Xc are pyridinium salts, wherein n=2, R+=PyH+, Y"=Br".
15. The soluble formulation according to claim 11, characterized in that the substitu- ents of general formula Xd are glycolates, wherein R=CH2.
16. The soluble formulation according to claim 11, characterized in that the substitu- ents of general formula Xe are selected from the group comprising glucosyl, galacto- syl, lactosyl and the 2-deoxyanalogues thereof.
17. The soluble formulation according to any of claims 11 to 16, characterized in that the cyclodextrin is selected from the group comprising native or substituted β- cyclodextrins and γ-cyclodextrins.
18. The soluble formulation according to any of claims 11 to 17, characterized in that the auxiliary substances are biocompatible organic solvents and compounds facilitating the formation of inclusion complexes.
19. The soluble formulation according to claim 18, characterized in that the biocompatible organic solvents are ethanol or propylene glycol
20. The soluble formulation according to claim 18, characterized in thabthe- compounds facilitating the formation of inclusion complexes are alkali carbonates or hy- drogencarbonates
21. A pharmaceutical composition, characterized in that it contains the soluble formulation according to any of claims 11 to 20 and a pharmaceutically acceptable solvent.
22. The pharmaceutical composition, characterized in that the pharmaceutically acceptable solvent is water.
PCT/CZ2007/000088 2006-09-27 2007-09-25 Method of preparation of a soluble formulation of water-insoluble pentacyclic and tetracyclic terpenoids, a soluble formulation of a pentacyclic or tetracyclic terpenoid and a pharmaceutical composition containing this soluble formulation Ceased WO2008037226A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA2666437A CA2666437C (en) 2006-09-27 2007-09-25 Method of preparation of a soluble formulation of water-insoluble pentacyclic and tetracyclic terpenoids, a soluble formulation of a pentacyclic or tetracyclic terpenoid and a pharmaceutical composition containing this soluble formulation
EP07801129.3A EP2068882B1 (en) 2006-09-27 2007-09-25 Method of preparation of a soluble formulation of water-insoluble pentacyclic and tetracyclic terpenoids, a soluble formulation of a pentacyclic or tetracyclic terpenoid and a pharmaceutical composition containing this soluble formulation
US12/443,304 US8653056B2 (en) 2006-09-27 2007-09-25 Method of preparation of a soluble formulation of water-insoluble pentacyclic and tetracyclic terpenoids, a soluble formulation of a pentacyclic or tetracyclic terpenoid and a pharmaceutical composition containing this soluble formulation
JP2009529508A JP2010504921A (en) 2006-09-27 2007-09-25 Process for the preparation of water-insoluble pentacyclic and tetracyclic terpenoid soluble formulations, pentacyclic or tetracyclic terpenoid soluble formulations, and pharmaceutical compositions containing the soluble formulations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CZ20060606A CZ300722B6 (en) 2006-09-27 2006-09-27 Process for preparing inclusion complex of pentacyclic and tetracyclic terpenoids, process for preparing pharmaceutical composition containing this inclusion complex, inclusion complex of pentacyclic or tetracyclic terpenoid and pharmaceutical compos
CZPV2006-606 2006-09-27

Publications (2)

Publication Number Publication Date
WO2008037226A2 true WO2008037226A2 (en) 2008-04-03
WO2008037226A3 WO2008037226A3 (en) 2008-07-31

Family

ID=39081570

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CZ2007/000088 Ceased WO2008037226A2 (en) 2006-09-27 2007-09-25 Method of preparation of a soluble formulation of water-insoluble pentacyclic and tetracyclic terpenoids, a soluble formulation of a pentacyclic or tetracyclic terpenoid and a pharmaceutical composition containing this soluble formulation

Country Status (6)

Country Link
US (1) US8653056B2 (en)
EP (1) EP2068882B1 (en)
JP (1) JP2010504921A (en)
CA (2) CA2666437C (en)
CZ (1) CZ300722B6 (en)
WO (1) WO2008037226A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ301158B6 (en) * 2008-09-01 2009-11-18 Univerzita Karlova v Praze, Prírodovedecká fakulta Triterpenoid derivatives for treating tumor diseases and pharmaceutical composition in which the derivatives are comprised
CZ301318B6 (en) * 2008-11-13 2010-01-13 Univerzita Palackého v Olomouci 2-Deoxyglycosides of triterpenoids, process of their preparation and their use as medicament
EP4472994A4 (en) * 2022-02-02 2026-04-08 Sang Hyun Pyo NEW BETULIN DERIVATIVES, METHOD FOR THEIR PREPARATION AND THEIR USE AS SURFACE ATTACHMENTS

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6372025B2 (en) * 2014-05-13 2018-08-15 日本製粉株式会社 Chewing composition containing triterpenes
JP2019052105A (en) * 2017-09-14 2019-04-04 国立大学法人静岡大学 Oleanolic acid derivative

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992009553A1 (en) 1990-11-21 1992-06-11 Hokkaidosugar Co., Ltd. Water-soluble pentacyclic triterpene composition and production thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2659466A1 (en) * 1976-12-30 1979-02-15 Roecar Holdings Nv STEROLINE AND THEIR USE
JPH04316597A (en) * 1991-04-12 1992-11-06 Kyokuto Internatl Corp Ferulic acid ester of triterpene alcohol-branched cyclodextrin molecular compound
JP4105258B2 (en) * 1997-08-19 2008-06-25 大塚製薬株式会社 Cholestanol compound and medicine containing the same
US6403816B1 (en) * 1997-09-30 2002-06-11 Dabur Research Foundation Betulinic acid derivatives having antiangiogenic activity, processes for producing such derivatives and their use for treating tumor associated angiogenesis
JP3282583B2 (en) * 1998-05-08 2002-05-13 株式会社微生物化学研究所 Adjuvant composition, vaccine using the same and novel saponin
KR20010080507A (en) * 1998-11-18 2001-08-22 추후보정 Novel betulinic acid derivatives, processes for preparing such derivatives and its use as cancer growth inhibitors
JP4351314B2 (en) * 1998-12-24 2009-10-28 大塚製薬株式会社 Cholestanol compound and medicine containing the same
GB2362648A (en) * 2000-05-23 2001-11-28 Univerzita Palackeho V Olomouc Triterpenoid derivatives
JP5052730B2 (en) * 2000-08-15 2012-10-17 ブリガム ヤング ユニバーシティ Steroid-derived antibiotics
DE10146500A1 (en) * 2001-09-21 2003-04-17 Beiersdorf Ag Cosmetic and / or dermatological combination of active ingredients
GB0128071D0 (en) * 2001-11-22 2002-01-16 Cyclacel Ltd Medicament
EP1594885B8 (en) * 2003-02-11 2009-03-25 Novelix Pharmaceuticals, Inc. Medicament for inhibiting tumour growth
MXPA06010592A (en) * 2004-03-17 2007-06-12 Panacos Pharmaceuticals Inc Pharmaceuticals salts of 3-o.
TW200628161A (en) * 2004-11-12 2006-08-16 Panacos Pharmaceuticals Inc Novel betulin derivatives, preparation thereof and use thereof
TWI373473B (en) * 2005-09-02 2012-10-01 Otsuka Pharma Co Ltd Anticancer agent

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992009553A1 (en) 1990-11-21 1992-06-11 Hokkaidosugar Co., Ltd. Water-soluble pentacyclic triterpene composition and production thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GEWEHR M., KUNZ H., SYNTHESIS, 1997, pages 1499
HEDGES A. R., CHEM. REV., vol. 98, 1998, pages 2035 - 2044
UEKAMA K., HIRAYAMA F., IRIE T., CHEM. REV., vol. 98, 1998, pages 2045 - 2076
URBAN M., SAREK J., TISLEROVA I., DZUBAK P., HAJDUCH M., BIO- ORG. MED. CHEM., vol. 13, 2005, pages 5527

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ301158B6 (en) * 2008-09-01 2009-11-18 Univerzita Karlova v Praze, Prírodovedecká fakulta Triterpenoid derivatives for treating tumor diseases and pharmaceutical composition in which the derivatives are comprised
CZ301318B6 (en) * 2008-11-13 2010-01-13 Univerzita Palackého v Olomouci 2-Deoxyglycosides of triterpenoids, process of their preparation and their use as medicament
WO2010054606A2 (en) 2008-11-13 2010-05-20 Univerzita Palackeho V Olomouci Triterpenoid 2-deoxy glycosides, method of preparation thereof and use thereof as medicaments
WO2010054606A3 (en) * 2008-11-13 2012-02-16 Univerzita Palackeho V Olomouci Triperpenoid 2 - deoxy glycosides and use thereof as medicaments
JP2012508696A (en) * 2008-11-13 2012-04-12 ウニヴェルジタ パラケーホ ヴ オロモツ Triterpenoid 2-deoxyglycoside, process for its preparation and its use as a medicament
EP4472994A4 (en) * 2022-02-02 2026-04-08 Sang Hyun Pyo NEW BETULIN DERIVATIVES, METHOD FOR THEIR PREPARATION AND THEIR USE AS SURFACE ATTACHMENTS

Also Published As

Publication number Publication date
CA2762911C (en) 2013-11-05
US20090325919A1 (en) 2009-12-31
CZ300722B6 (en) 2009-07-22
CZ2006606A3 (en) 2008-10-22
CA2666437C (en) 2012-04-24
EP2068882B1 (en) 2017-08-23
JP2010504921A (en) 2010-02-18
CA2666437A1 (en) 2008-04-03
WO2008037226A3 (en) 2008-07-31
US8653056B2 (en) 2014-02-18
EP2068882A2 (en) 2009-06-17
CA2762911A1 (en) 2008-04-03

Similar Documents

Publication Publication Date Title
BRPI0517752B1 (en) process for the preparation of drospirenone
EP2068882A2 (en) Method of preparation of a soluble formulation of water-insoluble pentacyclic and tetracyclic terpenoids, a soluble formulation of a pentacyclic or tetracyclic terpenoid and a pharmaceutical composition containing this soluble formulation
DE1618830B2 (en) Oxygen-containing llbeta-OB-13beta-C-gona-1, 3,5 (10&gt; trienes and process for their preparation
EP2213679B1 (en) Water-soluble triterpenephenol compounds having antitumor activity and the preparation thereof
US4332797A (en) Chlorambucil derivatives
CN104395318A (en) Polyoxopregnane compounds and use thereof
WO1999002177A1 (en) Pharmaceutical composition containing peptichemio
JP5566392B2 (en) Triterpenoid 2-deoxyglycoside, process for its preparation and its use as a medicament
CN113214340A (en) Antitumor glycyrrhetinic acid derivative and preparation method thereof
WO2018102974A1 (en) Conjugate for natural active ingredient cardiotonic steroid and octreotide, and preparation method therefor and uses thereof
Hachey et al. Syntheses with stable isotopes: Synthesis of deuterium and 13C labeled bile acids
JPH0678231B2 (en) Blood viscosity reducing agent
US3706727A (en) Steroid compounds effective against cardiac conditions and method of their preparation
EP0875515B1 (en) Sulfatation of estrogen mixtures
RU2426737C1 (en) 4-HETERO-16α, 17α-CYCLOHEXANOPREGNANES
JP2640239B2 (en) Protostar-13 (17) ene-3,16-dione compound
KR830002081B1 (en) Method for preparing chloram boric derivative
CN108341850A (en) Saponin derivative and its pharmaceutical composition and application
CN119350359A (en) A compound and its preparation method and application
JPS5970700A (en) 7alpha-alkyl-17alpha-pregn-4-ene-21,17- carbolactone and -21-carboxylate, manufacture and antialdosteronic pharmaceutic-al medicine
JPS5810397B2 (en) Novel estradiol derivatives, their production methods and antitumor agents
US3264285A (en) Novel 19-nor-testosterone-17-hemiacetals and -hemiacetal esters
BR112020005596B1 (en) PROCESS FOR PREPARING AN ANTIBODY-DRUG CONJUGATE INTERMEDIARY
CN113666895A (en) Halogenated 2-benzo [ c ] furanone compound and application thereof
DE1668205B2 (en) 16 ALPHA-ALKYLTHIO-9BETA, 10ALPHASTEROIDS, THE PROCESS FOR THEIR MANUFACTURING AND THE PHARMACEUTICAL PREPARATIONS CONTAINING THESE

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07801129

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2666437

Country of ref document: CA

REEP Request for entry into the european phase

Ref document number: 2007801129

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007801129

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2009529508

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12443304

Country of ref document: US